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INTRODUCTION
Cystic fibrosis (CF) was first described in the 1930s. The earliest account was
probably that of Blackfan and Wolbach (1933) under the title of ‘Vitamin A
deficiency in infants’.1 Most of the 13 infants in their series were autopsied, and had
the characteristic pathology in the pancreas, as well as suppurative lung disease.
They included two pairs of siblings. One of the pairs of siblings had been the subject
of a single published case report, ten years earlier. The authors considered that this
new disease of the pancreas was the cause of the vitamin A deficiency, but
concentrated their attention on the secondary avitaminosis and neglected to give it
a name. As a result, in Europe credit for recognizing what we now know as CF is
usually given to Guido Fanconi (1936),2 who published his paper in German, and
in the USA to Americans, Dorothy Andersen (1938)3 or Blackfan and May (1938).4
Clearly, a genetic disorder as widespread and common as CF must have been
around for a very long time before it was separately identified from the many
diseases causing death in infancy in the pre-antibiotic era. An indication of this
was given in the folklore of middle Europe, where grandmothers knew that the
child who tasted salty when kissed was bewitched, and would soon die (Busch
1990).5 But the disease is much older than that. A recent paper touching on the
antiquity of CF from the geneticist’s viewpoint concluded that some of the
common mutations in the CF gene may be older than the ethnogenesis process
that originated present European populations (Mateu et al. 2002).6
1 Blackfan K D, Wolbach S B. (1933) Vitamin A deficiency in infants. Journal of Paediatrics 3:
679–706.
2 Fanconi G, Uehlinger E, Knaver C. (1936) Das Coeliacsyndrom bei Angeborener zysticher pankreas
fibromatose und bronchiektasen. Wien Medizinische Wochenschrift 86: 753–56. See biographical notes,
page 94.
3 Andersen D H. (1938) Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and
pathologic study. American Journal of Diseases of Children 56: 344–99. See biographical notes, page 91.
4 Blackfan K D, May C D. (1938) Inspissation of secretion and dilation of ducts and acini. Atrophy
and fibrosis of the pancreas in infants. Paediatrics 13: 627–34.
5 Busch R. (1990) The history of cystic fibrosis. Acta Universitatis Carolinae Medica 36: 13–15. A well-
known passage from German children’s songs and games from Switzerland forecasted that ‘The child
will soon die whose forehead tastes salty when kissed’. 
6 Mateu E, Calafell F, Ramos M D, Casals T, Bertranpetit J. (2002) Can a place of origin of the main
cystic fibrosis mutations be identified? American Journal of Human Genetics 70: 257–64.
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We cannot go so far back, but this Witness Seminar was arranged to capture the
spirit of what it has been like to live through a period that spans early clinical
descriptions, increasing awareness, diagnostic problems (page 11), evolving
management for affected children and, increasingly, adults, medical mistakes (page
24), genetic and molecular definition (pages 59–63), and steadily improving
survival and hopes for the future. The recollections of some of the more senior
participants (for example pages 4–9, 16, 66) and eloquent testimony from a CF
patient (pages 71–3) may serve to deepen the understanding of younger colleagues
of the road we travelled before they joined the journey, and as a reminder that, ‘If
we see further than our predecessors it is because we stand on their shoulders’.7 And
what shoulders! – Harry Shwachman, Paul di Sant’Agnese, Giulio Barbero, Martin
Bodian, Dorothy Andersen, Charlotte Anderson and Winifred Young, to name but
a few giants who are no longer with us. It would have been interesting to have held
a similar seminar a generation or more ago, and had their input – but if we had, it
would have been from a different perspective. Thankfully, those who were still
available for this meeting [in the organizer’s words, some who regard themselves as
‘Johnny-come-lately’ (page 9)] were in good form: articulate and reflective. It was
good to be able to compare then with now.
Since the discovery of the gene in 1989,8 CF has often been quoted as an example
of how genetic research has led to a better understanding of intracellular
mechanisms of disease.9 Although there are now more than 1000 known mutations
in the relevant cystic fibrosis transmembrane regulator (CFTR ) gene, there are
already current clinical trials of targeted drugs to correct the consequences of the
various types of mutation, and perhaps even an eventual possibility of gene therapy.
If the momentum of the past 65 years can be maintained, there is good reason
for hope that the youngest participants will in the near future see persons with
CF enjoy a life expectancy not very different from their own (page 21). They
may some day recall that they were there when this little record was prepared.
Professor John Dodge (Monmouthshire)
7 Peter Medawar’s speech at the Nobel Banquet in Stockholm, 10 December 1960. From Les Prix Nobel
(1960). Stockholm: The Nobel Foundation.
8 Kerem B, Rommens J M, Buchanan J A, Markiewicz D, Cox T K, Chakravarti A, Buchwald M, Tsui
L-C. (1989) Identification of the cystic fibrosis gene: Genetic analysis. Science 245: 1073–80.
9 See, for example, Christie D A, Tansey E M. (eds) (2003) Genetic Testing. Wellcome Witnesses to Twentieth
Century Medicine, vol. 17. London: The Wellcome Trust Centre for the History of Medicine at UCL.
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1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to
Twentieth Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the
History of Medicine at University College London.
WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine
Group, as part of the Academic Unit of the Wellcome Institute for the History
of Medicine, to bring together clinicians, scientists, historians and others
interested in contemporary medical history. Among a number of other initiatives
the format of Witness Seminars, used by the Institute of Contemporary British
History to address issues of recent political history, was adopted, to promote
interaction between these different groups, to emphasize the potential of
working jointly, and to encourage the creation and deposit of archival sources for
present and future use. In June 1999 the Governors of the Wellcome Trust
decided that it would be appropriate for the Academic Unit to enjoy a more
formal academic affiliation and turned the Unit into the Wellcome Trust Centre
for the History of Medicine at University College London from 1 October 2000.
The Wellcome Trust continues to fund the Witness Seminar programme via its
support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held over 30 such
meetings, most of which have been published, as listed on pages xiii–xix.
Subjects are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. These inevitably lead to further
contacts, and more suggestions of people to invite. As the organization of the
meeting progresses, a flexible outline plan for the meeting is devised, usually
with assistance from the meeting’s chairman, and some participants are invited
to ‘set the ball rolling’ on particular themes, by speaking for a short period to
initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check his or
her own contributions and to provide brief biographical details. The editors turn
the transcript into readable text, and participants’ minor corrections and
comments are incorporated into that text, while biographical and bibliographical
details are added as footnotes, as are more substantial comments and additional
material provided by participants. The final scripts are then sent to every
contributor, accompanied by forms assigning copyright to the Wellcome Trust.
Copies of all additional correspondence received during the editorial process are
deposited with the records of each meeting in Archives and Manuscripts,
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the nonspecialist, the sense and significance of
the events are understandable. Our aim is for the volumes that emerge from
these meetings to inform those with a general interest in the history of modern
medicine and medical science; to provide historians with new insights, fresh
material for study, and further themes for research; and to emphasize to the
participants that events of the recent past, of their own working lives, are of
proper and necessary concern to historians.
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Professor John Walker-Smith: I would like to welcome you to this Witness
Seminar today. I am not here in any sense as a paediatric gastroenterologist, but
as a member of the History of Twentieth Century Medicine Group. I did have
some experience in the management of cystic fibrosis in general at the Royal
Alexandra Hospital for Children in Sydney before I came to England in 1974,
and I have been interested in the treatment of the small intestinal changes
occurring in children with cystic fibrosis in subsequent years.1
Although there were sporadic reports of pancreatic infantilism in the early part of
the twentieth century, it was the work of Guido Fanconi in Zurich that really
began the modern story of cystic fibrosis in 1928. In that year he published
observations concerning a group of children that he called the ‘coeliac syndrome’
with symptoms that dated from early infancy;2 yet the children also had bronchitis.
On an anecdotal note, I remember Guido Fanconi when I was research fellow in
the Kinderspital, Zurich, in 1967. He was called the ‘Old Fanconi’. At that stage
he was still a very tall and eminent figure, distinguished from his son, the ‘Young
Fanconi’, who later became a professor in Zurich as well. Then Guido went on
with Uehlinger and Knauer in 1936 to describe what he called ‘familial pancreatic
cystic fibromatosis with bronchiectasis’.3
Two years later, in 1938, the great Dorothy Andersen in New York reported on
20 infants from the Babies’ Hospital, New York.4 She described extensive autopsy
findings: widespread pulmonary infection, and destructive and cystic changes in
the lungs with fibrosis in the pancreas itself. So you could say that the era of cystic
fibrosis really began then. In fact, Jim Littlewood has assembled a good deal of
historical information about cystic fibrosis and people can get copies if they wish.5
We are not talking about these matters today. Today we are talking about living
history. This is just the introduction. What we are really concerned with now is
to hear what all of you observed and contributed yourselves, and how you felt,
caring for children and adults with cystic fibrosis, from your own experience. This
is living memory. Some of the questions that Tilli Tansey has asked in previous
Cystic Fibrosis
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1 Penny et al. (1986).
2 Fanconi (1928).
3 Fanconi et al. (1936). 
4 Andersen (1938).
5 Littlewood J. (2002) The history of the development of cystic fibrosis care, available at
www.cysticfibrosismedicine.com. See also Kulczycki (1990); Mearns (1993); Busch (1991); Doershuk (2001).
Witness Seminars, such as ‘What was it like at the time?’, are very important.
When you are making your remarks, we would like to get a flavour of what it was
like at the time. Another question that we would like you to consider when you
are speaking today is, why did things happen in the way they did? I am here, eager
to learn as much as you. I think this is going to be a very exciting afternoon.
The first topic that we are going to discuss is the development of clinical
knowledge of cystic fibrosis in both children and in adults. We are going to break
it up into two periods. First, we are going to look at the period 1945–55. This
will be followed by a discussion of the period from 1955 up to the present. So
it’s a very great pleasure to have here with us today Dr Archie Norman, whom
we know so well as a great contributor to cystic fibrosis. Archie, would you be
kind enough to begin this Witness Seminar by talking about your own
experience of the development of knowledge in the period 1945–55? 
Dr Archie Norman: Thank you very much, Mr Chairman, for your
introduction, but I am not quite so sure about the living memory part of it – I
will have certain difficulties there. The late Tom Macnair Scott from
Philadelphia, and Charles May from the Babies’ Hospital in New York, both
came to this country during the Second World War as part of the war effort, and
worked at Great Ormond Street Hospital, London. Charles May had written a
very good paper on cystic fibrosis in 1938 at the same time that Dorothy
Andersen’s much more extensive and authoritative paper really took over.6 So he
knew a good bit about cystic fibrosis. Incidentally, both Tom Macnair Scott and
Charles May spoke at the RSM [Royal Society of Medicine] in 1943, when
Charles May gave a paper on cystic fibrosis.7 This paper was probably the first
cystic fibrosis paper given in this country. 
It’s difficult nowadays to envisage what it was like in 1945, but for those of us
who had come back from the war to this country, it was an extremely exciting
period. So many new advances in medicine: paediatrics itself had become
accepted as a real branch of medicine, and not a junior part; there was the
discovery of the antibiotics that totally changed our attitude to infectious disease,
which was of particular importance, of course, regarding cystic fibrosis;8 last, but
Cystic Fibrosis
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6 Blackfan and May (1938). See Andersen (1938) and page 7.
7 May (1943).
8 Dr Archie Norman wrote: ‘The antibiotics gave us hope of controlling, or even eradicating, the chest
infection that was the cause of the mortality in cystic fibrosis.’ Note to Dr Daphne Christie, 4
November 2003.
not least, was the advent of the National Health Service in 1948. Why that was
important for cystic fibrosis, was that we could prescribe drugs without worrying
whether the family could afford them, a matter of immense importance in a
persistent long-term disease such as cystic fibrosis. In those days everything was a bit
primitive. Diagnosis of CF [cystic fibrosis] was made by the absence of proteolytic
enzymes in two stool specimens, and then confirmed by the very tricky and
uncomfortable business of duodenal intubation.9 I had a ward sister who was
particularly good at this, to the irritation of my registrars. The absence of trypsin
from a specimen of duodenal juice with reduced alkaline content was accepted as
confirming the diagnosis. 
Treatment – again primitive. The symptomatic steatorrhoea was controlled to
some extent by pancreatic tablets or powder, and by a strict low-fat diet, which
may not have been the best thing, but at least reduced the number of offensive
stools, and certainly reduced the amount of offensive flatus, which for
schoolchildren was very upsetting and unpleasant. The low-fat diet was supposed
to be supplemented by a high-protein diet, but as much as one insisted on
children having a high-protein diet, it was virtually impossible. These were still
the days of rationing; proteins of any sort, and particularly meat, were in short
supply and very expensive, and certainly there weren’t many children who
received even a normal protein diet by today’s standards. Chest infection, usually
considered to be staphylococcal, was treated with courses of penicillin and then
aureomycin, or terramycin, or whatever was coming along. Prolonged
prophylactic treatment was also tried, especially in the later 1950s, notably by
David Lawson at Queen Mary’s Hospital, Carshalton.10
Physiotherapy I think was really pioneered in this country, rather than in the
USA, with postural drainage and chest tapping. Surprisingly these very primitive
measures did decrease early mortality and at least temporarily improved the
outlook for the older and therefore less severely affected child. On the other
hand, the amount of interest and clinical research into cystic fibrosis in this
country was infinitely less than in the USA, and it is tempting to blame the
effects of the war for this. Martin Bodian was appointed to Great Ormond Street
as morbid anatomist in 1943. He soon began studying, in his very obsessional
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way, the histology of all the organs affected by cystic fibrosis with one single
exception, which was the genital tract in males, and which was later shown to be the
cause of infertility.11 Cedric Carter and I joined him in 1950 to cooperate on his
book Fibrocystic Disease of the Pancreas, which was published in 1952,12 and in this
book Carter established for the first time that cystic fibrosis was due to a recessive
gene.13 Elsewhere, Baar from Birmingham published in 1953, a thoughtful article,
highly critical of some of Bodian’s theories,14 but it isn’t widely accepted today. He
and Bodian were by no means friends. There must have been more work going on
in Birmingham at that time, but I haven’t found anything that has been recorded.
Of those very few other developments with regard to CF that I can find in
Britain at that time, Winifred Young was appointed to the Queen Elizabeth
Hospital for Children, Hackney Road, London, as a research clinician in 1948,
and established a cystic fibrosis clinic in 1950 which was highly successful.15 At
Great Ormond Street I had a fairly large number of children with cystic fibrosis,
and developed a team of dieticians, physiotherapists and social workers, who saw
each family every time they attended. Ruth Harris, Wilfred Payne and I
published a little paper on the effect of pancreatin therapy on fat absorption and
nitrogen retention.16 Apart from that, not a great deal of interest was shown in
cystic fibrosis in this country, and there was certainly a tendency to believe that
it did not occur at all in certain regions. That is all I have to say, except that from
the beginning we got the impression that the children with cystic fibrosis were
exceptional in the way in which they overcame their difficulties, in their
determination and in their intelligence. 
Walker-Smith: Thank you for a very fine beginning. Who else would like to
make any comments about this early period?
Dr Philip Farrell: I am from the University of Wisconsin Medical School. It’s a
pleasure to be here, with my wife Alice. She and I started out in the 1960s, she
as a medical technologist performing sweat tests, while I was taking care of
children with cystic fibrosis. 
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Since you are interested in the period 1945–55, I would like to describe my
experience of working with Paul di Sant’Agnese. I had the privilege of working
with Paul for five years at the National Institutes of Health, and I heard him on
many occasions describe his experiences of working with Dorothy Andersen,
going back to 1938, after he graduated from the University of Rome Medical
School and travelled to New York for his residency in paediatrics at the New York
Postgraduate Hospital.
As many of you know, Dorothy Andersen was a paediatric pathologist, not a
clinician.17 Although Dr Andersen didn’t take care of children with cystic
fibrosis, she was an astute pathologist and in her seminal publication she made
the connection between ‘cystic fibrosis of the pancreas,’ the title of her article,
and the occurrence of chronic suppurative lung disease.18
Dr di Sant’Agnese told me many times about the programme at the Babies’
Hospital at Columbia University in New York and why it was so successful. I
would like to share some of that information with you and a few other
comments from another American paediatrician, Dr Lew Barness, who was very
active then in Boston, New York and at the Children’s Hospital of Philadelphia.
Paul di Sant’Agnese told me that the greatest difficulty, and Dr Norman alluded
to this earlier, was in actually establishing the diagnosis of cystic fibrosis. He
emphasized that duodenal intubation was the key to making the diagnosis of
cystic fibrosis by demonstrating pancreatic insufficiency, before his discovery of
the sweat electrolyte abnormality in 1952.19
I think this Witness Seminar is timely, because we are celebrating the golden
jubilee of the discovery of the sweat electrolyte defect. It was in April of 1952
that Dr di Sant’Agnese made this discovery of the high sodium concentrations
in the sweat of children with cystic fibrosis.20 Dorothy Andersen hired him to
take care of her patients because, not being a paediatrician, but rather a
pathologist, she lacked the ability to take care of the children that were referred
to her for care, that is the 600 patients referred to her for care in New York. 
There were four reasons why they were referred to the Babies’ Hospital and why
it became such an important centre. First, of course, the seminal publication 
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I mentioned previously, and her knowledge of the pathology and the
pathophysiology of cystic fibrosis. Second, the combination of her reputation
and arrogance. Dorothy Andersen said that she was the only person in the world
who really knew about cystic fibrosis back in the late 1930s and even in the
1940s. She was the self-proclaimed expert, and paediatricians of that era, such as
Lew Barness, told me that Dorothy travelled around the east coast saying that
she really was the only person who knew about cystic fibrosis. Third, parents
were absolutely desperate whenever this diagnosis was suspected. Lew Barness
told me that the two worst diagnoses in paediatrics at the time were cystic
fibrosis and acute lymphocytic leukaemia. Both diagnoses were a ‘death sentence’
because in each case you knew that the disease was fatal and the paediatrician had
to tell the parents that the child was likely to die within a matter of months,
generally within a few months if the child with cystic fibrosis had advanced
pneumonia without antibiotic therapy available to treat a staphylococcal
pneumonia.21 The fourth reason was that New York City was the one place in the
USA that anyone could reach easily and that parents, being so desperate when a
child was suspected of having cystic fibrosis, often came to New York for care.
They came to Dorothy Andersen, but she didn’t actually take care of the patients,
but rather it was Paul di Sant’Agnese who served this vital role. 
So it’s very significant that Paul was the person who became essentially the right
arm of Dorothy Andersen in the care of children with cystic fibrosis. He was
devoted to this clinical role, but the situation was often hopeless once the
diagnosis was made, particularly if there was already progressive lung disease
from Staphylococcus aureus. Paul had some reluctance to do duodenal drainage
studies, because the results, as Dr Norman just pointed out, were frightening
once the laboratory tests demonstrated low levels of pancreatic enzymes –
frightening in the sense that the prognosis was so grave, once the diagnosis was
established. As Dr di Sant’Agnese once said and I quote: ‘We watched them get
progressively worse and eventually die, after making the diagnosis.’
The first break in treatment came after the Second World War when penicillin
became available.22 Paul di Sant’Agnese had access to penicillin from the US
Army. The US Army of course was the organization in the USA with top priority
in obtaining penicillin, but Paul was able to obtain it. I don’t know if he did this
on the black market, or how he got the penicillin, but he had enough penicillin
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available to create what he called ‘miracles’ in response to antibiotic
chemotherapy using aerosolized penicillin.23 Paul told me that it seemed to make
no difference how the penicillin was given, whether it was given by aerosol, or
by parenteral therapy.24 In his judgement, the Staphylococcus aureus was so
exquisitively sensitive to penicillin that any treatment with penicillin in these
children with progressive staphylococcal pneumonia could be effective. I
remember vividly, Paul telling me when I was his clinical research fellow what a
wonderful feeling it was, and how exciting it was to be able essentially to cause
miracles through treatment with penicillin in these children who otherwise were
going to die within weeks or months; patients slowly dying from the chronic
pulmonary disease revived in a few days. For the first time there was an effective
tool to help control the lung infection as the predominant organism in the
bronchi of patients with CF. Patients who had never had an antibiotic before
were very susceptible, even though by present standards ridiculously small doses
were used. Penicillin was effective even by routes that were considered quite
unconventional, namely aerosol inhalation, which of course we now use to treat
Pseudomonas aeruginosa infections in children with cystic fibrosis. A key
discovery was the sweat electrolyte defect. I will just take a few minutes to review
the history of that.
Walker-Smith: I think we might just leave sweat electrolytes for the moment, as
in the second session we are going to talk about diagnosis. What we have just
heard is a fascinating account – we have been given a picture of a very grim
situation, although some optimism was appearing during this period. We are
now moving on to the more modern period, 1955 onwards. Jim, would you like
to carry it forward?
Dr James Littlewood: Yes, I feel a bit embarrassed here, because I was, as
Margaret Mearns will tell you, a rather ‘Johnny-come-lately’ to cystic fibrosis,
having worked in a provincial city as a consultant paediatrician for many years
before gradually more cases seemed to be coming along and I started a CF clinic
in 1975. But as I notice from the general paediatricians in this country, they have
always felt that they could deal with cystic fibrosis. There are even some today
who believe that there is no need for specialists in cystic fibrosis. 
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But if we go right back to when I qualified in 1956, as a locum I was trying to
get sweat off people, putting their limbs into Bunyan bags, which were used in
the war for burns, and scraping these drops of sweat off to try to confirm the
amazing finding of the heatwave of 1948 and the observations of di
Sant’Agnese and Darling in 1952 and 1953.25 It was also quite scary in those
days, because people were wrapping children up to make them sweat and there
was more than one fatality reported due to overheating, trying to get sweat. It
was marvellous when the pilocarpine iontophoresis method became available,26
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Figure 1: A 20-month-old child (b. 1991) – patient of Dr Mary Goodchild – being
tested by pilocarpine iontophoresis using the older type of sweat-test box. Photograph
provided by Dr Mary Goodchild, 2003. Goodchild and Watson (1995): 187. 1995 
© CRC Press. Reproduced with copyright and parents’ permission.
that was really a massive advance for everybody (see Figure 1).27 Also at that
time, I think it is fair to say, there was some progress in the USA. In 1958 there
was the classic Shwachman and Kulczycki paper, with 105 patients that
included their details of clinical score.28 There wasn’t really a great deal going
on in the clinical side in the UK that we could see from the periphery in the
provinces. In the 1960s the outlook for CF was absolutely appalling. In one of
Sydney Gellis’s comments in the Yearbook of Pediatrics, (I don’t think he
seemed to get on with Shwachman very well, because he was always knocking
him in these little comments you get in the Yearbook), he said, ‘Despite claims
to the contrary, cystic fibrosis of the pancreas continues to carry a gloomy
prognosis. Present-day therapy is helpful but offers relatively little, and a
realistic alteration of the course of this disorder will require a major
breakthrough in discovering the aetiology.’29 Well, actually, things have
improved a great deal; I think he wasn’t quite correct there. 
But through the 1960s, what happened then? Terrible outlook, very few patients
around, therefore very little call for CF centres apart from the few centres that
we have heard about like GOS [Great Ormond Street] and the Queen Elizabeth
Hospital [London], very little call to get patients together, because there weren’t
many patients. Archie, you may recall a study you did with Dr Mantle, looking
at the survival from the 1940s to 1964, and 80 per cent had died by the age of
five, 90 per cent had died by the age of ten, and there were no adults.30 There
must have been a few, because Sir John Batten started his clinic in 1965 at the
Brompton, London, so there must have been some adults, somewhere, but there
weren’t many in the north – I can tell you that! 
The Cystic Fibrosis Trust (initially the ‘Cystic Fibrosis Research Trust’) started in
1964.31 I suppose the clinical item for discussion in the 1960s was LeRoy
Matthews talking of the mist tent as a breakthrough in 1961.32 This became very
popular in the USA and we all got the odd mist tent for our patients and they were
sweating away in these at night. In 1967 Matthews published a paper supporting
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the value of the mist tent33 and di Sant’Agnese said that anybody with adequate
experience of this disease knows that it works.34 However, by the beginning of the
1970s there were a number of papers showing that mist tents didn’t work at all.35
But, Archie, you did a study on this and you said you had the impression that some
of the patients did benefit from it.36 I must say, my one patient in a mist tent did
seem to do rather well in it, but who knows? Mist tents went out of fashion.
Norman: At the time I thought the principle of the mist tent was mistaken and
that it was not really effective. As Jim says, I might have changed my mind over
one or two cases, but I was never very convinced by the basic principle of it.
Mrs Mary Dodd: I worked for Professor Aron Holzel in Manchester in the
1960s, looking after the children there, and all of our children used to go in mist
tents, and at one time there was the theory that if we put seawater in the
ultrasonic nebulizers, something to do with the iodine and the seaweed would
actually benefit the patients. We used to go to Treaddur Bay, off Anglesey; that
was the best seawater to collect and put into the ultrasonic nebulizers.
Littlewood: Some people used to use iodides, didn’t they, as a sort of mucolytic?
Dodd: I think that was the principle behind it.
Professor John Widdicombe: It seems to me the use of the mist tent so long ago
was very prescient, because it’s only in the last few years that people have talked
about hydration of mucus as a way of treating cystic fibrosis pharmacologically,
and presumably the mist tent was doing this years and years ago, simply
hydrating the mucus which was not then known to be dehydrated.
Sir John Batten: I have been very fascinated, and delighted, to find that Archie
Norman is here, because he has been a great friend ever since I first saw a case of
cystic fibrosis with Winifred Young in her clinic. Margaret Mearns was there at
the time, and from that time when I did start a clinic for older patients at the
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Brompton in 1965, that’s the first documented case we had recorded. I have
never used a mist tent. 
Norman: I think the basic problem with the mist tent was of getting a sufficient
number of droplets of a small enough size in sufficient quantities to enter the
lungs and this really couldn’t be done.
Littlewood: Just to round off the 1960s, where I don’t think a great deal was
happening. At the end of the 1960s, [Beat] Hadorn wrote a series of very
important publications on direct measurement of pancreatic function,37 pointing
out the characteristics of the pancreatic secretion, which was really very useful.
Some of us enthusiasts obtained triple lumen tubes and spent a lot of time
irradiating people in the X-ray department, doing pancreatic function tests at
that stage. Warren Warwick started, I think, the very first CF database in about
1968 and I remember for many years he was at every meeting talking about his
CF database,38 and the importance of collecting data. 
There were various descriptions of polyps, meconium ileus equivalent,
reproductive failure in males, abnormal vas deferens, eye changes with
chloramphenicol and xerophthalmia with vitamin A deficiency. The first
description of jejunal biopsy came in the early 1960s, and many of us started this
towards the end of the 1960s39 – I know that was Margot Shiner – am I right? The
first paediatric series was carried out by Charlotte Anderson.40 [Professor Ian
Booth: No, Winifred Young actually did small bowel biopsies at the Queen
Elizabeth Hospital in 1958].41 Unfortunately a paper from Great Ormond Street,
attesting to the dangers of this in children (I think with Sir Wilfred Sheldon’s name
on it and Eddy Tempany) set us back in the provinces a long way because our
professor wouldn’t let us do any biopsies until 1968.42 But I won’t go into that here. 
Walker-Smith: That was the story of the inappropriate use of the adult small
intestinal biopsy capsule43 in children. I remember when I started at the Children’s
Hospital in Sydney there had been three perforations of the small intestine and
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one death following small bowel biopsy, due to the use of the adult capsule in
children.44 This was because the hole size was too large in the adult capsule. The
correct size for children is a porthole diameter no greater than 2.5mm.45
Littlewood: I only started them really to save the children from adult pathologists
who did biopsies with these huge capsules! Anyway, I digress. On to the 1970s.
Still very gloomy, no real CF centres in the UK, not a great deal of advance, but
I think there was a ray of hope from Margaret Mearns in 1972.46 Far from this
early demise of patients, I think you [Margaret Mearns] showed that from 1957
onwards children were doing very well up to the age of five, which was a very
different experience from many places in the country that didn’t have specialized
clinics. Høiby in Denmark was also looking at his antibodies to Pseudomonas,
using crossed immunoelectrophoresis, in the late 1970s.47
Mist tents were laid to rest, as I mentioned. Professor Bob Elliott, in New
Zealand, an amazing man, a sort of medical inventor, had treated a child with
CF with Intralipid and noticed a fall in the sweat electrolytes, and an amazing
change in this child compared with other children with CF in Auckland at the
time.48 He was also the person who, in 1979 with Crossley, described and
introduced immunoreactive trypsin neonatal screening,49 which of course has
become one of the standard methods of neonatal screening. 
So there was quite a bit happening and in certain places the outlook was
improving, but I can assure you that things were not improving in most cities in
the UK. Pancreatitis was described in people with residual pancreatic function.
Intusussception and the prolonged neonatal jaundice was described, the latter I
think by Bernard Valman, with a good prognosis, and then inevitably at the end
of the 1970s, misdiagnosis: ‘Does this child really have cystic fibrosis?’ by Christine
Smalley, Doug Addy and Charlotte Anderson, the first of many papers showing
misdiagnosis due to erroneous sweat tests50 – a very, very important paper.
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An amazing decade of progress took place in the 1980s. Why was that? Well, as
somebody was saying earlier, there were major improvements in the giving of
antibiotics, but it really was an astonishing period. One of the main influences
on clinical care was the work of Phelan and Hey, which I think John Dodge was
aware of before it was published in 1984,51 which showed a difference in survival
between England and Wales, and Victoria, Australia.
Professor John Dodge: I went to Australia in the early 1980s in the wake of the
paper by Phelan and Hey, which compared survival in the UK with that in
Victoria, and claimed that the average survival in England and Wales was about
15 years at that time, compared with over 21 years in Victoria. Unfortunately,
the methodology was different, because in the UK what they did was to get all
the death certificates of children or adults who had died with cystic fibrosis and
calculated the mean age of death. Whereas in Victoria they did a sort of standard
survival curve, which included all the living patients, and said ‘Well, this is all
because you don’t look after your patients properly in the UK, you should put
them all in big clinics’. So I went to Australia to see what they did, and when I
came home the Cystic Fibrosis Survey was set up to see what the true picture was
in the UK.52 Perhaps I should comment on that later. 
Littlewood: I think it was that finding which was instrumental in forming the
British Paediatric Association Working Party on Cystic Fibrosis which you [John
Dodge] chaired and which was formed in 1982,53 and which concluded that
people with CF should be seen in, and have access to, a cystic fibrosis centre. I
think this has been central to the improvement in CF centre care, with enough
patients pulled together, as had been happening at Great Ormond Street and the
Queen Elizabeth Hospital, but in many other places, and through the 1980s
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there were these really quite important developments. The Cystic Fibrosis
Research Trust started funding clinical staff, rather than just research, and they
even changed the name from the CF Research Trust to the CF Trust, because
they started funding staff in clinics – CF teams, as you obviously had, Archie, at
Great Ormond Street in the 1950s, but not many other people did. There were
teams of experts like Anita MacDonald, the dietician, and the physiotherapists,
the social workers, who became very expert in dealing with cystic fibrosis, and
this is when more rapid progress occurred – these people looking at the children,
seeing the problems on a daily basis and then trying to do something about it;
more aggressive antibiotics, for example the classic paper in 1981 by Margaret
Hodson and the people from the Brompton on the use of nebulized carbenicillin
and gentamicin.54 Around that time many people were worried about spraying
an aminoglycoside down somebody’s throat. Now, of course, they do it with
impunity, and at great expense – nebulized antibiotics for the chronically
infected. It was also shown in a short letter to the Lancet, which we wrote in
1985, that chronic infection with Pseudomonas was not inevitable; you could
eradicate early Pseudomonas by giving them nebulized colistin.55
Also, there were important papers on nutrition around that time56 and we didn’t
have dieticians involved in the 1970s, certainly where I was anyway. And in fact
a lot of children with CF, when it was gone into by a dietician, were not having
enough to eat. So we got the dieticians involved and also enteral feeding. I may
be wrong here, but I think the first enteral feed in an adolescent with CF was by
Tony Axon, an adult gastroenterologist from Leeds, who was referred a
malnourished girl. He put her on nasogastric elemental feeds and she did quite
well for a time but, of course, not in the long term.
Walker-Smith: I think we will just pause there and ask Sir John Batten to tell us
something about the adult services that were developed. We have heard already
how he was the innovator at the Brompton Hospital;57 would you like to carry
on and tell us what happened? 
Batten: As I mentioned earlier on, we had five cases that had been reported in 1965,
at a special clinic for cystic fibrosis. Just to bring you up to date, we now have 650
cases attending that clinic at the Brompton, masterminded now by Duncan Geddes
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and Margaret Hodson who, I am sorry to say, couldn’t be here today. She has been
a great part of our team there and apologizes for not being here. 
So what can I tell you about treating adults? One is, of course, that it would be
sensible if one approached the need for these special clinics, we all know that, but
it’s still not understood to the full in the country as a whole, that patients not in
a special clinic don’t do very well, and this has all been established by careful
studies.58 So we have our clinics, we have well-defined protocols, we have careful
record-taking, and I think we have witnessed in the UK an amazing change in the
use of special clinics. I don’t think I want to go on for very long, because most of
you know what is needed in a clinic and what is required these days for treatment.
Walker-Smith: So we do have a very clear message then from both the children’s
and the adult services of the development, and the need for the special clinics.
These very positive outcomes you were telling us about, Jim, have in a large
measure stemmed from that. 
Littlewood: Yes. Just in case I forget to mention it, a massive advance in
nutrition was the introduction of Pancrease (acid-resistant microspheres) in the
late 1970s, first recorded in the North American CF club meetings. I remember
a poster in Toronto, Canada, by Holsclaw on this,59 describing Pancrease going
through the stomach protected from acid by its covering and then into the
duodenum and, of course, it proved to be a revolution in enzyme management,
allowing the low-fat diet to be abandoned in most patients. The other thing I
must mention, in case I forget, is the home intravenous (IV) treatment, which
allowed for much better and more acceptable IV treatment. The totally
implantable venous access devices were good for people having repeated IVs,
and, on the human side, the local anaesthetic cream (EMLA cream), which
allowed you to insert a needle without pain; that was an enormous advance both
for the children and for people actually having to do the work.
Then came heart–lung transplantation in 1985 – a massive advance for people
in the terminal stages.60 Gradually publications came from Denmark, which
seemed to be ignored by many, that aggressive IV antibiotic treatment
significantly improves the condition and survival of the patients.61 Then, rather
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Figure 3: Selected cohort (males) and interrupted cohort (both sexes) survival for the UK.The
upper four lines are the selected male cohorts, the lower three are the interrupted (both sexes)
cohorts. From Hodson and Geddes (2000): 19. Reproduced by permission of Hodder Arnold.
Figure 2: Current survival, males. From Hodson and Geddes (2000): 18. Reproduced by
permission of Hodder Arnold.
more worryingly, came the first reports of Burkholderia cepacia,62 a virulent organism
that has totally altered the patients’ social lives and their medical management.63
But I remember running a ‘tertiary’ referral service for CF through the 1980s
in Yorkshire, and some of the patients referred were in a really terrible
condition, they had never had any intravenous antibiotics and it was really
very distressing. I tried to get a paper published on this in the late 1980s and
it was not accepted by any journal, because the editor of one leading journal
said that it was too critical of the care that these patients were receiving, and
so it was never published. It’s actually in the abstract book of the 1988
Australian International CF Congress.64 There was another interesting paper
from the USA around that time, by Wood and Piazza, comparing the care in
three CF centres in the USA, showing amazing differences in survival.65 The
better centres saw the patients very frequently, and gave more days of
intravenous antibiotics. 
Walker-Smith: I think at this stage we might bring John Dodge in, concerning
the changing outcomes and treatment. John, would you like to carry us forward
and tell us how things began to change in terms of the outcome of children who
were being treated?
Dodge: I hope most of you had a copy of two graphs from Duncan Geddes’s and
Margaret Hodson’s book (Figures 2 and 3), and really they sum up what
happened.66 If you look first of all at Figure 2 you will see current survival in
different countries of the world, UK, Canada, USA and Victoria, Australia, and
there’s not much between them. As it happens, Victoria, which started off the
discussion, seems to be doing rather worse than North America and the UK, but
there’s not a lot between them – although they have very different health systems
and very different ways of delivering healthcare. 
The UK data came from the UK Cystic Fibrosis Survey set up by the British
Paediatric Association and the British Thoracic Society,67 and funded by the CF
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Trust, and, as Jim says, he was one of the members of the working group, as was
Margaret Mearns. We tried to do two things: first of all, find out what was the
true survival in the UK, not just from death certification, and second to try to
see if there was a difference between patients managed in large and small clinics.
We didn’t have any way of defining a CF centre, other than by size, and it was
quite clear that those patients managed in large clinics were doing better. Now
when you look at the second figure (Figure 3), which shows selective cohort data
for different cohorts of patients born between 1947 and 1988. It doesn’t go
beyond that, because 1988 was the last group that we could properly study,
because the survey came to an end in 1995 and we haven’t had an update since
then. But if you look at the top four lines, the oldest cohort of patients born
1962 to 1964, clearly the mortality was much higher in them than in the later
cohort, children born after 1986. 
But you will also see that there was a very big drop in the first year of life in the
earlier cohorts, and that has almost gone. The reason for that was nothing to do
with paediatricians and nothing to do with heart–lung transplant or anything else
developed recently. It was all because babies no longer died with meconium ileus.68
That’s down to the credit of the paediatric surgeons, and it had a bigger single
impact on survival than anything else that we have done before or since. In this
country it was Harold Nixon at Great Ormond Street, and in the USA it was
Charles Koop in Philadelphia, who showed that these children did not have to die,
that surgery could save them. Archie Norman showed many years ago that survival
in the Great Ormond Street meconium ileus patients, who survived the immediate
post-operative period, was actually rather better than the general run of CF
patients.69 One of the reasons why our data in Britain for a long time were thought
to be rather less good than those from the USA was that for many years the USA
survival curve did not include patients with meconium ileus because they were
thought to have a slightly different disease, and so they were excluded. But if you
included them, you can see that a lot of them died young in the first year. 
Now that that no longer happens, the other thing that is happening is that the
lines are gradually straightening off. The chapter by Peter Lewis, a statistician,
not a doctor, that this print was taken from, goes on to say: ‘It’s now beginning
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to look as though predictions of a 60-year survival are quite realistic.’70 The
current survival in the UK is probably of the order of about 35 years mean,
although we don’t have up-to-date figures. When you think that in 1900, the
average survival for all males in Britain was about 40 years, it shows you how far
we have come.
Walker-Smith: So this is really a triumph, isn’t it, in terms of survival? A
tremendous change in the period that we are talking about. 
Norman: Just one point about special clinics. Although the health service now
is supposed to be very short of money, in the 1950s and 1960s various hospitals
were equally short of money, and not only was there a natural conservativism,
which tended to prevent our elders and betters from allowing us to establish
special clinics, but the cost of them was quite considerable. It was difficult to get
the nurses, dieticians and so on, time to come to any special clinic, or there
weren’t enough of them, anyway, to come.
Professor Sandy Raeburn: My view is from the northerly Celtic fringe, Scotland.
In 1965 Professor Ellis noticed the need for somebody to look after CF patients
and he appointed a young paediatrician called W Morrice McCrae, who set up the
CF clinic in Edinburgh.71 Later in the 1960s, I think two other things were
happening that were affecting care in what were becoming more specialized clinics.
First of all, there was better laboratory support for the clinics, the ability to work
with the bacteriologists and choose the right antibiotics for a particular infection. 
I think a second feature, too, was that the pharmaceutical industry was perhaps
trying to help test its own products by offering some of them free to CF clinics. 
I must make one comment, which is an adverse comment about the effect of
special clinics that I discovered rather belatedly. We had a special CF clinic in
Edinburgh for quite some time and the family doctor was often squeezed out.
We had the multifactorial team policy, with physiotherapists, nurses, doctors,
dieticians, everybody in the hospital environment, but when the patient
deteriorated and perhaps was dying and wishing to remain at home during those
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last few weeks, we had a GP who had scarcely met this 20-year-old individual. I
think that was something that was eventually starting to be put right, perhaps as
a secondary effect of intravenous therapy at home, and certainly in the 1990s,
the psychosocial effect was recognized.
Professor Duncan Geddes: Just three comments about the late 1970s and early
1980s. I worked with John Batten as a senior registrar at the Brompton, and one
of the things that got me into cystic fibrosis was the evidence of the benefit of
specialist aggressive units. You would see these children coming in from the
paediatricians, either from those like Margaret Mearns who had looked after
them well, or from general paediatricians who really hadn’t, and the difference
was very striking in the quality of the people at the age of 16 to 18. Then you
could see when they came into hospital sometimes just how much you could
improve them. They would come in malnourished, badly infected, really dying
and, with intensive treatment, you could actually pull people right back, and that
convinced me of the importance of both a positive approach and special clinics. 
It is worth remembering the impact of nihilism on the patients and their families
before that time, many of whom had been told, ‘Your child will die at the age of
five, oops, all right, by the age of ten. Still alive – well, wait until 15’, and we
would then inherit them with this feeling of nihilism and negativity running all
the way through that child’s life. The second main point was the enormous
difference in dietary management as we went from low-fat diets, from dietary
restriction in people who were undernourished, to Pancrease and high-fat diets,
and suddenly people’s weight took off, and instead of inheriting very
malnourished sort of sexually immature 18 year olds from the paediatricians you
began to get these rugby first-row forwards coming through. 
The third point is the sort of epidemiological cohort trap that a number of adult
physicians fell into. I certainly did on starting a clinic, because I inherited patients
just about the time that the median survival was reaching the age of 18, so
patients came to me and then they died within three years. We thought that it was
something that we were doing wrong, but as we stuck with it a little longer, we
realized that they died at 24 or 26 and it wasn’t our fault entirely after that. The
benefits of centralized care became evident at that time but it took about ten years
before all the debates finally stopped and it was accepted by everybody.72
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Dr Maurice Super: I first encountered cystic fibrosis in Windhoek in South
West Africa [Namibia], as it was called at the time, in 1967. I inherited a
patient who had been looked after by the paediatrician who had left there two
years before, and his care had been neglected and I admitted him to hospital.
He looked much as what Duncan Geddes mentioned a moment ago, almost
at death’s door. On active antibiotics, pancreatic enzymes and physiotherapy,
he gained 4 kg in ten days in hospital. This particular boy was then for many
years one of the less ill patients on our cystic fibrosis clinic, because, although
I was on the edge of the medical world, I read a lot and I realized the
importance of setting up a clinic. But unfortunately at the age of 16 he
attempted to take his own life. Why? Because he and his parents had been
told that he would not survive beyond the age of 12. He finally did die at the
age of 24. The other thing is that if you work in a place where more or less if
you say cystic fibrosis is your interest, that’s it, and you do what you like in a
way. I read Elliott’s work on Intralipid73 and we had a monthly meeting of the
parents and of the CF clinic staff, and while we were having this general
meeting, the children sat on the paediatric ward and they were all given
Intralipid for an hour, intravenously. 
Just very anecdotally, which I think we have been encouraged to do, an
Australian locum who came up to look after my patients once when I was on
holiday, was struck by how healthy the children were and how little Pseudomonas
there was. I don’t ascribe that to the Intralipid, I ascribe that probably to the very
dry atmospheric environment of South West Africa.
Littlewood: I was just going to say the Intralipid stories resulted in the first
controlled trial of nutrition by Chase and colleagues in 1979,74 where it was not
shown to be of any significant benefit. 
Farrell: I don’t think the point has been emphasized yet, but it is very important.
We now know about the variation in severity and the milder forms of cystic
fibrosis. I believe that one of the major lessons of the last decade or so is that this
disease is so protean in its manifestations and has such a variable prognosis, that
one has to be cautious about not over-treating and taking on unnecessary risks,
and so I wanted to comment briefly about the risks. There have been numerous
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iatrogenic problems with this disease, related both to diagnosis and treatment.
The purpose of this seminar and the purpose of studying history is to learn the
truth; and the truth is that we have done many things with CF patients that have
been harmful to them. Sweat-test bags caused deaths. Jim mentioned one death;
there were many deaths that just weren’t reported. 
Mist-tent therapy was a source of P. aeruginosa; there is no question about that
adverse effect of a commonly used ‘treatment’. Mist tents also caused increased
airways obstruction. There are papers that report decreases in airflow after mist-
tent exposure. 75 The psychosocial harms of mist tents are absolutely incalculable.
I remember well that I stopped recommending mist tents to my patients in
about 1973, because one was getting married and she wondered if they should
take the mist tent along on their honeymoon. I said to this young couple, ‘It’s
time to stop the mist tent’. The research on mist tents causing ‘a decline in
ventilatory function’76 had just been published, and I had cultured P. aeruginosa
from mist tents. Frankly, it was time to stop using this misguided strategy. 
Other iatrogenic adverse effects are attributable to antibiotics, such as
tetracycline staining, and fragility of teeth and bones.77 Harry Shwachman told
me once that physicians had no choice at one time and that the benefit
outweighed the risk, but as his patients aged he told me how much he hated to
see them come back with teeth that were ruined by the treatment he gave when
they were younger. Gentamicin is another problem. Soon after we started to use
that first aminoglycoside antibiotic, the problem of deafness and nephrotoxicity
was recognized,78 and we over-treated patients and, frankly, they paid a price.
Finally, oral prophylactic antibiotics are unquestionably one of the factors in
increasing the risk for P. aeruginosa. I think it’s one of the reasons we began to
see P. aeruginosa emerge. You rarely find it reported in the literature on cystic
fibrosis prior to the advent of broad-spectrum antibiotic therapy.79
Pancreatic microspheres are another source of harm as well as benefit. I agree
with Jim [Littlewood], they were miraculous, but the more recently introduced
high-strength pancreatic enzymes can cause severe colonic strictures, and now we
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are paying a price for that also. Cystic fibrosis camps were developed to improve
psychosocial opportunities for these children. However, they turned out to be
extraordinarily damaging as a source of cross-infection or person-to-person
transmission of B. cepacia and, I believe, P. aeruginosa. And you can go down the
list. I know of children who deteriorated while receiving Intralipid when severely
ill, so I think we have to take the responsibility for the harm that we have caused
as well as the good that we have achieved.
Walker-Smith: That’s a pretty grim story, outlining all the bad things the doctors did.
Littlewood: We were talking about fat and Duncan was saying how important
it was that they got enough to eat with a decent enzyme. A man who influenced
me a lot, although I never met him, was [Doug] Crozier from Toronto and his
1974 paper, ‘Cystic fibrosis: A not so fatal disease’.80 I read it if I am feeling
depressed. He insisted that you did a thorough assessment of every aspect of the
patient and then repeatedly tried to get everything back to normal. Am I right
in thinking that he was the man that really gave up low-fat diets, pumped people
on 60, 70, 80 Cotazym capsules a day and – what’s the word he said – it’s
ridiculous to reduce fat in children who are so skinny?
Farrell: It was the Toronto CF centre more than any other cystic fibrosis centre
that promoted the shift from low-fat diet to normal or high-fat intake with
higher doses of pancreatic enzymes. This change is attributable to the leadership
of Doug Crozier.
Littlewood: In his clinic it preceded the new enzymes, didn’t it? 
Farrell: It did, but remember there’s one other factor in Toronto and this is a
factor I mentioned before. The enormous number of patients referred there
meant that they were receiving patients with relatively mild mutations and
pancreatic sufficiency, as we found out later, so patients that were not so severely
ill, and that’s one reason the statistics look good.
Littlewood: Patients who needed to get there [to the Toronto Centre], rather
than dying locally. 
Dr Anita MacDonald: Can I just make a comment on the introduction in
changing low-fat diets to high-fat diets, which occurred very much in the early
1980s?81 My background is as a dietician; I started working in Leeds in 1980. I
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think there has always been a general assumption among physicians that if you
tell a patient to do something they will always do as they are told. What actually
happened in Leeds, when we started the systematic assessment of dietary intakes,
was that many of the patients were already on a normal-fat intake. They had
abandoned the fat restriction. Pancrease wasn’t used until the 1980s.82 What we
saw clearly was that the patients who were cheating and actually eating a high-
fat diet were doing far better, in terms of growth, than the patients who were
keeping to the original low-fat diet. So it actually bore out the very early work
that had been done by Crozier and Chung.83 This was before the new enzymes
became available.
Walker-Smith: It shows you how important dieticians are in the care of 
these children.
Professor Kevin Webb: I think I would like to turn round Dr Farrell’s comments
slightly. There are a few withered, ageing adult-CF physicians in this room, and
I think the only reason we exist actually, is because of the superb care of the
paediatricians who sent their patients to us, for which I blame them in a positive
way really, because I don’t think we would exist if it wasn’t for them. It was the
twentieth anniversary this year of our CF unit and I have never forgotten when
I emigrated to north Manchester, which was a sort of Third-World district where
they fire guns at each other, Mary [Dodd], who had looked after the children,
said, ‘When are we are going to look after the adults?’ and I looked around and
said, ‘Where are they?’ And they were all in the children’s hospital still. They were
shipped over in a cartload because the paediatric hospital had had enough of
them at the age of 16, and we took over this really grumpy bunch of 16–20 year
olds at that time. 
Going back to Duncan’s words, and really CF centre care isn’t anything clever,
actually, it’s the delivery of finite, multidisciplinary care. There were two of us
who started off and now there are 40 of us, and that’s really why, apart from the
paediatricians, the mean survival over the last 20 years in fact has gone from
about 22 to 34. It’s nothing clever, the advances came beforehand, it’s really the
finite multidisciplinary care of physiotherapists, doctors, social workers and
dieticians, who put it all into the patients. 
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Raeburn: Two quick anecdotes from Morrice McCrae, which illustrate the
difficulty of transfer from paediatric to adult care. Morrice said that he knew it
was time to transfer them to an adult physician, when first of all they grew much
too tall for the toilets in his paediatric wards and, second, when they asked him
directly for contraceptive advice.
Walker-Smith: It does touch on a more general problem in Britain, which is the
failure of adolescent medicine to really take off in the way that it has in the USA.
In many chronic diseases of children such as Crohn’s disease, care of the
adolescent is a very difficult matter. In such circumstances it is now accepted that
the paediatrician and the adult physician should meet together at the handover
clinic, where adolescent patients are actually handed over personally.
Raeburn: I think Jim could say more about this, but in the Scottish system I was
a physician and a geneticist. Therefore I played a part in the transfer to adult
care, but clearly as a geneticist I didn’t have active use of beds, so a link-up
developed in which I was a cog between the paediatricians and then the adult
chest physicians in north Edinburgh.
Walker-Smith: Can I ask a more general question? Was it the custom to have the
paediatrician and physician meet over the patient? Did they actually have a
hand-over clinic anywhere in the country?
Raeburn: What tended to happen was that some of us came to the paediatric
clinics for several months and met people there, but despite that, transfer was
very difficult. 
Littlewood: I think many people used to run a transition clinic for a year or two,
and it was staffed by a paediatrician, an adult physician and staff from both
units, so that over two or three years they would get to know the members, and
then the move there would be a gradual transition, when they wanted to go in,
they would be shown the adult unit, and then could go in if they wanted. If they
didn’t want to change, they could stay on until 16 or 17, if they wanted to move
very quickly, they could go quite quickly. I think most units now have it
organized, but it has been a point of discussion for a long, long time, with, I
think, a lot of unnecessary difficulties. But remembering the problems we had in
the early days and the adult ward I tried to transfer patients to, I know the
difficulties can be considerable.
Sir Christopher Booth: I would like to know something about the relationship
between paediatric and adult medicine. My experience of this came through
coeliac disease and Winifred Young at the Queen Elizabeth Hospital for
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Children [London], who sent me patients from 1960 onwards, and we
developed a joint arrangement. I think that developed in respect of coeliac
disease all over the country.
My question about cystic fibrosis is, at what stage did this happen? What sort of
date did these things begin to happen? Was the development of cystic fibrosis
influenced by other conditions, for example, people with genetic diseases living
on into adult life? Where did the pressure come from? Was it the paediatricians
or did it come from adult physicians?
Dodge: The outcome of our first survey was that we produced a document that
recommended that specialist CF clinics should be set up when there were about
50 patients,84 and I think we recommended that that should apply to adult
clinics, as well as to children’s clinics. In those days there were fewer adults than
children, today there are probably more adults with cystic fibrosis in Britain than
children. That means that if you want to have a viable clinic, with all the
different specialities represented – the physios, the nurses, the dieticians and so
on – you do need a core number of patients of the order of 50, to make it
financially and professionally viable.
I think it has become easier to transfer patients now, because, of course, one
group that nobody has really mentioned has been the cystic fibrosis nurses. I
think they often act as midwives in taking the child into the adult clinic in a way
that perhaps doctors no longer need to, because we can leave it to our expert
nurses to arrange the hand-over. Obviously, we send over the notes and
everything else, but we don’t need a physical hand-over from doctor to doctor.
Dr David Stableforth: I just wanted to return to the subject of transfer from
childhood to adult clinics. When I first went to Birmingham in 1977, having
been trained in John Batten’s unit at the Brompton Hospital, London,
Birmingham had a very large childhood clinic, but as far as I knew on arrival
there, and having an interest in looking after these patients, there were few
adults. They were scattered around the region, and there was a Professor
Anderson in the paediatric clinic at Birmingham.85 At that time she was resistant
to all approaches that she should hand over her patients. [Booth: It wasn’t just
cystic fibrosis.] I can remember an interview, going to see her in 1977 to
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persuade her that I could look after adult patients, and just a very small number
of new patients were referred to me after that meeting. There was this large
growling dog under her desk, I think there to intimidate me! 
Anyway, following that meeting, about five patients followed over the next five
years from her, and it wasn’t until my colleague, Dr Peter Weller, arrived in
Birmingham that there was an agreeable relationship between the paediatricians
and the adult physicians. Following his arrival in the early 1980s we developed a
transition clinic of the type that Jim Littlewood has talked about. Peter Weller
and myself, and members of the multidisciplinary team, all sitting down in the
consultation room – a rather intimidating group I feel in retrospect – and the
adolescents and adults would come in and sit down, and the child would be
handed over in that way, perhaps not at the first visit, but at subsequent ones.
That’s now all been streamlined and the transition clinic is now looked upon as
very important for the smooth transfer of care from the childhood to the adult
cystic fibrosis clinic.
Walker-Smith: Those remarks about Charlotte Anderson are extremely
interesting. Incidentally, Charlotte Anderson died on 15 April of this year
[2002], in Melbourne. Dr Goodchild is from Charlotte Anderson’s unit.86
Dr Mary Goodchild: Following on a little bit from the remarks just now: I also
remember this dog, a poodle I think and not too large, but it definitely growled.
But to be serious for a moment and straying slightly into the role of the CF Trust
which is the next item on the agenda, there was a very nice survey and investigation
of the actual mechanics of transferring from a paediatric to an adult clinic done
very thoroughly by a lady whose name I forget at the moment [Jean Pownceby],
commissioned by the CF Trust.87 She went around many of the clinics in England
and for all I know in Scotland as well, and worked out a number of factors that
were necessary for a smooth transfer from paediatric to adult clinics. One thing
that was very clear, from the patients’ point of view, was that the last people they
wanted in the clinic when they attended as patients were their parents. 
Walker-Smith: I can echo that in chronic inflammatory bowel disease, the
children really wanted to talk to the doctor on their own. 
Ms Susan Madge: Talking about transition and the comment that was just made,
often the problem with the transition seemed to be the parents. I used to work
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at Great Ormond Street, and transition started when we found that we had
children surviving and they weren’t dying, and I think that’s what prompted us
into it, the expectation of a longer life ahead for them. One or two survived and
they were just moved by letter almost, to the Brompton, but as the population
of survivors grew, then transition became more of a serious subject, and the
children then became very eager to move, but the parents seemed to be the ones
to hold back, and to put the brakes on. Eventually everyone moves, because it’s
a children’s hospital and everyone has to be out of there, and having guidelines
helped us. It was often the parents that were reluctant to lose that trust that they
had had for 16 or 17 years, and the faith they had had in the people caring for
their children, and it was often that which seemed to be the problem.
Walker-Smith: I visited Harry Shwachman in 1966 at the Boston Children’s
Hospital. There, they had pregnant girls cared for in the Children’s Hospital.
Harry was very reluctant for the young people to go over to the adult hospital.
Dr Peter Hunter: Could you explain exactly what was different about pancreatic
microspheres in getting effective pancreatic enzyme action into the right part of
the gut? It’s been a problem throughout most of the twentieth century. What was
special about this device, and when and where was it discovered?
Littlewood: Pancrease and Creon are the trade names for the two new acid-
resistant pancreatic preparations. The thing that was very special about
Pancrease, and later Creon, was that they were not destroyed by stomach acid, so
the actual enzyme was not released until the surrounding environment became
alkaline in the duodenum or even a bit further down. Whereas before, as di
Magno showed in the 1970s,88 the vast amount of exogenous enzyme powder is
destroyed in the stomach, leaving only a tiny little bit of it. Pancrease sounded
like a gimmick initially. I can never forget seeing the poster in Toronto, but by
Jove it was miraculous! I can well remember a girl of about 15 weeping when she
had been put on to Pancrease, and saying that her whole life, as I think Archie
was suggesting, was dominated by her terrible bowels, and she said, ‘Now I can
live a normal life’. It was absolutely awesome, the effect in some patients. I
pushed it hard because it was a very, very important area.
Hunter: Let’s come to a much more serious point – a point about ‘why did
things happen the way they did?’, and ‘why did things happen at the time they
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did?’ I would like to look at this from the point of view of the history of drug
discovery and specifically the discovery of streptomycin by Selman Waksman.89
The second point is that he opened up that new area of microbiology; he
discovered actinomycetes and defined them. Then we come to an extremely
important point; that is the question of how he was financed. In 1940 he had
tried and succeeded in obtaining from Actinomyces antibioticus, the antibiotic
actinomycin A, and this was highly toxic. The next thing that happened was that
he was given a very significant amount of money. Basically discoveries tended to
happen because a private source of money, a charitable source, financed a person
and then a drug company did the same thing.
Booth: Can I just stick to the question of special clinics? One of the problems
for those looking after patients in such clinics, dealing with patients with genetic
disease, is a danger that a man and a woman may fall in love with each other,
following their time at the clinic. My question therefore is, has anybody here any
experience of that happening in his or her clinic and, if so, what was the outcome
in terms of children? 
Webb: I don’t know quite how to answer that. Our patients fall in love with each
other all the time. I am in charge of sexual morals on the ward and ask the advice
from the sisters, because of the cohabiting that goes on. And that is absolutely
serious. We have had patients leave their spouses to associate with others, and
some of them actually do have very strong relationships and live with each other.
Part of the problem obviously is with the inevitable sequelae if the patients don’t
get a transplant, there are no offspring from two CF patients, because the men
are sterile, so that’s quite fortunate, and male sterility is the only thing one can
think of that is fortunate. But the cohabitation of two CF patients can and does
cause a lot of grief.
Stableforth: I just wanted to recall a very special grief which was historically
rather important to our clinic at Birmingham Heartlands – East Birmingham
Hospital as it was then – when a couple fell in love. A young man with cystic
fibrosis in 1990, or 1991, had acquired B. cepacia infection, possibly from
contact with someone who had been to a Canadian cystic fibrosis camp, and he
met and fell in love with and was shortly to marry a girl who also had cystic
fibrosis, and she grew Staphylococcus aureus only in her sputum. Within two
months of the start of that relationship, this girl had acquired Pseudomonas
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cepacia, as it was then called. The young man died within six or eight months of
their meeting, following a lung transplant operation and three months later the
young woman died. This terrible event alerted us to the facts of this dreadful
infection by which so many clinics in the UK have been so scarred over the years.
This is a problem which we are only now getting to grips with through
segregation and other infection-control measures.
Geddes: Just to extend that a bit. The love between patients is one problem, but
love between patients and members of staff is another, and that too can be quite
a difficult thing to handle, with medical or nursing staff leaving their spouses
because they have become so intimately involved with the patient. It’s something
that’s very seldom talked about, but I have seen enough of it, and I bet a lot of
other people have too. 
Webb: Yes, I have seen that. I have to echo what Duncan says, the CF patients
have an enormous charisma, we have had at least four very strong relationships
between male CF patients and the nurses who look after them, and a couple of
them are getting married. There are obviously the inevitable consequences that
apply to that as well. I always find it rather odd, and always have found it rather
odd, that if a doctor was in such a situation he would be struck off [the Medical
Register], but it doesn’t apply to the nursing staff.
Walker-Smith: May I ask Margaret Mearns what her views are about transition
clinics – children-to-adult clinics?
Mearns: I was very fortunate because I could go to the Brompton when the
patients were due to be transferred and I could attend the clinic with them, and
I think I went most weeks to the Brompton, even if there weren’t any new
patients. I could either sit in on the consultations or I could see them at the side
and then discuss their progress over the previous weeks with the consultant in
charge of their care.
Walker-Smith: So you actually introduced the children to the physician? [Yes.]
Farrell: I want to comment on the role of the CF patients in pressuring
physicians and nurses to transfer them to an adult-care setting. This was our
experience. Many patients who required repeated hospitalization for intravenous
antibiotic therapy, as they became older than 18 years, absolutely insisted on
transfer to another care setting. They wanted to come to our cystic fibrosis centre
for care, but they no longer wanted to come to the Children’s Hospital or to the
children’s clinic, and so some of them just insisted that we transfer them. These
admissions for intravenous antibiotic therapy, these tune-ups in the hospital that
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would last a week-and-a-half or two weeks, allowed us really to train the adult
pulmonologists to care for these patients. Then, subsequently the patients would
be seen in a specialized clinic at the medicine department, that is chest medicine
clinics. I think the patients themselves played a pivotal role as well as the nurses,
as Dr Dodge mentioned. 
Walker-Smith: You didn’t develop adolescent clinics?
Farrell: We didn’t develop adolescent clinics, and we didn’t think it was really
necessary because in our centre we were accustomed to taking care of both
children and adolescents.
Mrs Fran Duncan-Skingle: It was in 1980, when I started as clinical nurse
specialist at the Royal Brompton, that Sir John Batten, Professor Margaret
Hodson as she is now, and Dr Mearns were running joint clinics for transition
from paediatric to adult care. It’s taken a long time to initiate transition clinics,
and we are still talking about it 20 years later. But it is happening in most
centres now. 
Super: When Kevin Webb first came to Manchester, I had thought that it
would be a good thing if we did a couple of transition clinics, but Kevin said,
‘No’, and Gary Hambleton and I accepted that, but we also spoke to the
children from the age of about 12 onwards, telling them that at the age of 16
they would be moving, and it was seen as a positive milestone in their lives. Our
CF nurse and Kevin’s social worker used to be the transition links between the
particular patients and Kevin was absolutely right, none of those people have
ever come back to us, or asked to come back to us, they found it a great thing
to have moved.
Littlewood: I must say I think I agree with Fran [Duncan-Skingle]. It seems a pity
that we are discussing transition clinics after 20 years. Just to put a spanner in the
works, if you go to Denmark and speak to Christian Koch and his nurses, and the
lovely staff there, and ask, ‘What about the adults?’ They say, ‘Well, they are
attending this clinic’. And I say, ‘What about the transition?’ They say, ‘We have
known them since they were small, and we go on looking after them’. Of course
they have different clinic days, different wards, different everything, but the same
people. So I said I used to find it difficult about birth control, as a paediatrician,
and he said, ‘Oh, the nurses talk to them about it’. And I thought ‘It seems to run
very well’. I wouldn’t approve of it, but I just thought I would mention it. 
But in Leeds we had problems initially, but fortunately had a doctor working in
paediatrics [Steven Conway], who moved to infectious diseases, and
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subsequently became a consultant in infectious diseases. We started moving the
adults with CF in his direction, and now he has developed one of the biggest
adult centres in the country, but he started treating both children and adults, and
he’s still doing both as lead clinician of the Leeds Regional CF Clinic. 
Dr Tilli Tansey: May I ask a question about something that has been raised by a
couple of speakers? CF camps. Is this a North American phenomenon, and are
they also in Britain? How were they started? Could somebody tell us more about
CF camps, please?
Dodge: They were started in North America. But the CF Trust prevailed upon
some of us to start camps in this country. There was a Scottish camp, I think,
Sandy? [Raeburn: Yes.] And we certainly ran one in south Wales for a number
of years and Scottish kids used to come to our camp and ours used to go up to
Scotland, and we had them from Ireland and from Wales and England, and I am
sure they all infected each other, but they had a jolly good time, and we had
volunteers, physios, nurses, doctors and, of course, Ron Tucker. Nobody has
mentioned Ron Tucker yet, but I am sure he will be mentioned later. Ron was
the driving force behind a lot of these things. 
I think, with hindsight, camps were a bad thing. At the time they seemed awfully
good. They were certainly good for morale, and the thing that astonished me was
that when the professionals were totally exhausted by about midnight, and had
just sort of slumped into sleep wherever they happened to be, the kids were still
racketing around until the early hours of the morning. I don’t know where they
got their energy. 
Raeburn: Two very quick comments. One comment just to finish the earlier
theme, which is that clearly there was a psychological issue in the medical and
professional staff themselves about the transfer to adult care. We have got to
learn from that, as Philip says, it wasn’t just the psychology of the patient nor the
psychology of the parents, it was the psychology of the doctors and nurses. We
need to consider that, too. 
We ran two or three very successful CF camps that were very much watersport-
based in Scotland in the middle 1980s. We realized that infection was a possible
problem, and we did pre-camp testing and we did post-camp testing. Within the
short duration of those camps (one week), we weren’t able to show that there had
been cross-infection. I am quite sure, as John [Dodge] says, that learning
afterwards there was a problem demonstrated that we just could not test, with
enough precision. 
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Goodchild: I thoroughly agree that the camps were on the whole very enjoyable,
but we had a very unfortunate experience in Cardiff where I was working most
recently: one girl went over to Canada and brought back with her a genotype of
Pseudomonas cepacia, which John Govan would know about, a particular strain
of Pseudomonas cepacia (or B. cepacia as it became known later on), which
became the lead for six further cases of Pseudomonas cepacia of the same type in
patients who became infected at the Paediatric Clinic at the University Hospital
of Wales.90 So this was very unfortunate and the original strain almost certainly
emanated from that camp in Canada.
Walker-Smith: That’s very interesting indeed. Now I think we need to change
over to the role of the Cystic Fibrosis Trust, and it’s a pleasure to have Dr Tony
Jackson here, who is going to tell us about that.
Dr Anthony Jackson: Thank you, Chairman. I was Chairman of the Trust’s
Research and Medical Advisory Committee from 1984 to 1994. John mentioned
Ron Tucker. Actually what happened was that Ron Tucker invited me to lunch.
As you know there’s no such thing as a free lunch, and I ended up as the successor
to Archie Norman as Chairman. What I remember most of my ten years in the
research committee was, first, the gradual development of the attitude that the
Trust should be supporting clinical development, specialist centres and so on, by
funding clinical fellows and nurses and how, at first, the scientific members of the
committee rebelled against this, saying that this was not proper research, and we
certainly should not provide staff for the NHS. 
We managed, I think in the end, to accept the role of the Trust and we did really
make very strong efforts to get a centre in every region. I remember going round
some of the more distant parts of the country with my colleague, Martin Scott,
who was the scientific adviser, and seeing some of the arrangements. For example
– well, I had better not say where – somewhere in the northern part of the
country, there would be four or five different hospitals, with four or five different
adult physicians treating one or two patients each. The paediatricians were not
much better, except they had three or four patients each. But, I think, as a result
of providing money for those who followed the theme of developing a regional
centre, we gradually spread the number of centres throughout the regions. 
The other thing I remember most is the constant discussion we had about the
type of laboratory research we should be doing. Of course we had many, many
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discussions about how gene research was going (and we indeed put a great deal
of money into research in that line), particularly its merits or dismerits, and it
was rather disappointing for the Trust that the gene was not discovered in our
research laboratories, but in North America. 
The other thing we did was to start on heart–lung transplants. I have got in front
of me here the notes of an ad hoc meeting that was held on 1 August 1984 and
most of the people on this nominal roll are here today: John Batten, John Dodge,
Duncan Geddes, John Widdicombe and myself. The only other person not here
is the surgeon John Wallwork. This was a meeting at which we had to decide
whether or not heart–lung transplant was a possible or feasible approach in cystic
fibrosis and whether or not the Trust should support it. In fact as time went by
the developments, as you know, were that heart–lung transplant was certainly
fully developed and became a useful component of treatment. In fact there was
one time I remember when we made a grant of £500 000 to the Brompton
Hospital for the development of heart–lung transplantation. 
The other thing that we were concentrating on at the end was the matter of John
Dodge and his UK CF survey,91 which the Trust supported, and we used to have
regular meetings. I think we used to meet at Heathrow, John, didn’t we? [Dodge:
Yes.] Because John came from Belfast, and the statistician came from Cardiff. At
any rate, the Trust got involved in that and supported it, and was, I think,
instrumental in gradually merging the statistical activities regarding cystic
fibrosis with the Scottish database, and I think this has now become the UK
National Database.92 Those are some of the things I remember that we did in our
research advisory committee.
Walker-Smith: It’s interesting that in the early part of your remarks, you describe
a historical reluctance for specialization to develop. This is quite an important
theme that is coming through today.
Booth: Two fundamental questions I would like to ask: one is where does the
money come from, and secondly did you have lay people on your research
committee? Did you have patients on it?
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Jackson: We did not have patients on the Committee, but there was the pressure
for doing clinical research, as opposed to basic research. In those days we didn’t
have lay people, and perhaps Rosie could answer the question about money.
Mrs Rosie Barnes: The money comes from a variety of sources. There is always
a hardcore of money each year raised by the families of those coping with cystic
fibrosis, their schools, their Brownie packs and community initiatives, often
supported by families. That tends to bring in up to £2 million a year and has
been fairly recession proof. 
Over and above that, we have turned to charitable trusts, corporate sponsorship,
legacies, the National Lottery – there’s nobody we don’t ask – and most people
eventually give us something, because we won’t go away until we have got it. But
there is a backbone of patient support and very often the big donations we get
from companies will come about as a result of somebody on the inside, perhaps
with a child with cystic fibrosis, asking their company to bear us in mind when
making their charitable decisions for the year. 
Walker-Smith: And you have lay people now?
Barnes: We now have an adult with cystic fibrosis on our Research and Medical
Advisory Committee, and we would have another one were it not for the
problem of cross-infection. We now also have a parent of a child with cystic
fibrosis on the committee.
Walker-Smith: We do have a patient with cystic fibrosis here today. 
Ms Tracy Humberstone: To be honest, I am keeping quiet because I do not wish
to deter anybody in the room from saying anything that may be of interest to me
or to others present, or to restrict them. I am making notes, but I would rather
speak later. I have a number of points: e.g. ‘tetracycline’ staining. I do have severe
tetracycline staining to my teeth and if anybody wishes to see the damage, please
feel free.93 There are many concerns, i.e. the nihilism, age barriers, and so forth,
but I am sitting here absorbing the contributions. 
Barnes: There are one or two things that perhaps I could follow on with, which
have been mentioned today, from the Cystic Fibrosis Trust perspective. First, we
offer clinical support grants to 27 paediatric CF centres throughout the UK, but
only 17 adult centres, and so, although we are talking about the number of
adults versus the number of children, and the arrangement of the transition, one
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of the problems we have faced in parts of the country was there was nowhere for
them to transit to. It’s worked better and moved faster in some areas than in
others and obviously there’s still a shortfall there, which we need to address. 
I think it’s also important to say that although we talk about as many or more
adults than children now, that only seems to hold strictly true if you make the
dividing line at 16 years old, and by the time you get to 18 or 21, you are looking
at relatively few adults compared with those younger than that age.
Approximately 6000 of the 7500 CF patients in the country are 21 or under.
I would like to make a comment from a study done by the Cystic Fibrosis Trust
on transitional arrangements and parents.94 Both adults with cystic fibrosis and
their parents, not interviewed in pairs, or the same parents of particular children,
both admitted to a sort of conspiracy against their medical teams, with adults
with cystic fibrosis pretending to be far more independent in terms of managing
their CF than they in fact are. They go off and manage all sorts of other aspects
of their lives very independently, but they tend to leave their CF a bit at home,
and it’s very often the parents that come to Cystic Fibrosis Trust branch
meetings, put out medication for their adult child to take and continue to do
their adult child’s physiotherapy, even though the adult clinic may have taught
them to do it independently. 
But there’s been this great pressure for those becoming adult with cystic fibrosis
to become completely independent in a way that I think has been rather false, in
that if you got a new condition at the age of 17 or 18, you wouldn’t be expected
to manage it all on your own, as has sometimes perhaps been the case with cystic
fibrosis. One or two of the things that have been mentioned today, are areas
where the Cystic Fibrosis Trust has made changes over recent years. We started,
as the early talks we had today indicate, very much as a support group for the
parents of children with a life-threatening disease, and we have had to learn to
change, to be responsive to adults with the condition as well, and that’s
something we are taking on board. We try to fill the gaps in what the state just
won’t or can’t do, so apart from the database which we fund, we have funded
quite a lot of complex work and facilities in the area of microbiology that just
might not have happened had the Cystic Fibrosis Trust not facilitated it. I think
the fact that we have facilitated guidelines in recent years has been a great tool
for both the clinical teams and indeed patients to lobby with, to get better care
in their areas, and we are now pioneering an advocacy project where we employ
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12 adults with cystic fibrosis to be the user representatives for their particular
region, which I am hoping is going to be a great success. 
But I would just like to conclude with an anecdotal story of today, which shows
there’s still no room for complacency. I got a phone call yesterday from the father
of a girl aged 13, who, he told me, was not expected to survive, she was in hospital
and her medical team had told him to prepare for the worst. I asked which hospital
she was in and it was clearly a local district hospital, and I said what do her CF
centre team say? He said that she has never been to a CF centre. So although we
are making great strides, we do have to make sure that the ‘St Elsewheres’, as Jim
and I often describe them, somehow get brought into the equation. 
Walker-Smith: One would have thought that this reluctance to accept the need
for paediatric specialities would have been dealt with ages ago. In fact it is a
general problem still, and it’s rather shocking that we still have this occurring in
this country.
Norman: I would like to say something about the formation of the Trust, if Mrs
Barnes isn’t going to do so later. In the late 1950s, I think, John Panchaud (who
was a Swiss businessman) came to me. I was looking after his daughter who had
cystic fibrosis, and he said that he wanted to form a parents’ association. Now in
those days, parents’ associations were not looked on with great favour by many
doctors, partly because of the activities of the Spastics Association.95 However, I
thought this was a good idea, and I supported him in it. He then spoke to David
Lawson, whom he knew from Carshalton, and he agreed, too. John Panchaud
went ahead and formed this, with the support of Joe Levy, a very successful
businessman, who was a business colleague.96
Joe Levy put in an immense amount of time and money in supporting the Trust.
He was one of the most generous of men, and that is really how the Trust got
going. As far as the research committee is concerned, I and David Lawson and
Winifred Young got together and we then appointed David as Chairman of the
Research Committee of the Trust, but we were agreed that at that time it should
be a research trust in order that the maximum amount of money could go to
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research. We had no idea then, of course, how much Joe and his colleagues
would supply, and how much the Trust itself would raise later.
Dr Richard Boyd: I was on the RAMAC [Research and Medical Advisory
Committee] for a number of years and took pleasure in being a scientist trying
to find out at what point the clinical application of research findings was picked
up by the NHS in the way that Tony mentioned. But I think there’s a larger
general issue here: how does a very effective charity behave so that it does not
pick up the slack, the proper province on the one side of the National Health
Service and on the other side the MRC [Medical Research Council] and, dare I
say it, even the Wellcome Trust? I would like to hear a little bit more about the
Chairmen’s views. We have got three eminent Chairmen covering the Trust for
the last 35 years. It would be interesting to know if they felt they were ever
picking up the brief that properly belonged to other people. 
Jackson: Yes, we knew we were, and we were criticized by some paediatricians at
any rate in saying that we were providing, for example, a research fellow who did
the work of a registrar as well, and we were expecting that this would be taken over
by the NHS in due course, but we were criticized because it was made clear that
the NHS was not going to take these people over and once you had started the
specialized clinic that these people allowed, it became very difficult not to continue
with this. Certainly we were anxious about the amount of money we were putting
into the NHS, but the benefit to the patients was such that we felt the [CF] Trust
was doing a good job for the patients by doing so. Certainly the intention was
largely to stimulate the activity of a centre and then to back out and let the centre
make its own way. Many of them did. But I still remember it as being a difficult
time for us, and certainly the amount of money we put into laboratory research
and scientific research, as opposed to clinical research and the support of the NHS,
didn’t seriously fall, because the amount of money being collected gradually rose.
Walker-Smith: This is quite a common theme, isn’t it? I know both in cancer
research in children and also research concerning Crohn’s disease, that
substantial sums are given by private charities to maintain the health service.
One might argue that the health service has a real debt to such bodies.
Madge: I think it was important that the CF Trust funded these early posts. I was
funded originally by the CF Trust, but the NHS didn’t recognize the posts we
were taking on, they were unexplored, no one knew what they were about, and
the NHS wasn’t going to start funding them, so the CF Trust was needed to show
and to prove the worth of these posts. Most of the specialist ones have been taken
over by the NHS – not all, the Trust still funds some – but they would never
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have got going if we had had to wait for the NHS to start funding them. I tried
for years to get the funding out of the hospital. Before the Trust took it up we
were trying to go to drug companies for sponsorship. So I think the CF Trust
was important and unique in recognizing the innovation of new posts and
funding them so that the NHS would then take them up.
Barnes: If I could just clarify the outcome, following on from what Su Madge
has said. Over 92 per cent of the posts that the Cystic Fibrosis Trust has funded
within the NHS have been taken over by the NHS, we haven’t then withdrawn
the money, we have allowed it to be used to extend the teams even further, so we
do feel that we have got very good value for it. It’s pegged at around £800 000 a
year. We don’t allow it to go beyond that. We don’t allow it to run away with
itself, but I think we work on the principle that in terms of families coping with
CF we are trying to offer and ensure the best for today, and even better for
tomorrow. We feel that with all the research funding in the world, unless we can
be sure that families are getting the best, we won’t be honouring our part of the
obligation to them in the here and now. 
Walker-Smith: So it’s pump-priming you are doing really, isn’t it? It is very important.
Littlewood: Richard Boyd, I think you were actually asking about the MRC, the
other side of research, rather than clinical care. I always found that very difficult
to grasp. The Cystic Fibrosis Trust receives research applications from scientists
who are often receiving grants from the MRC, Wellcome and other sources. It’s
always very difficult to know exactly what proportion of that piece of research
you are funding. I don’t know. Did you find that, Tony [Jackson]?
Stableforth: Can I just first of all speak as a recipient over many years of
numerous grants from the Cystic Fibrosis Trust and say that without any
question my own hospital trust, or district as it was then, would not have allowed
the development of cystic fibrosis and the multidisciplinary team that has gone
with it, without pump-priming from the Trust, and in almost each and every
case the posts that they enabled to be created have been taken over by the
hospital trust. We are all enormously grateful for the Trust for that.
Littlewood: I would support that entirely.
Goodchild: May I extend that very slightly and say that in my view and, I think,
in the view of many people, the work done by the CF research fellows was so
good and so committed that it actually played a major part in raising the
standard of CF care throughout the country; for this I think that we have to
thank the Cystic Fibrosis Trust.
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Stableforth: I just want to make a point that has not been alluded to by Rosie
Barnes or others speaking about the Cystic Fibrosis Trust, which is the help that
they are now extending to the centres that want to build their own buildings to
house the patients and the multidisciplinary team. We know that there are a
number of centres throughout the country that they have helped a great deal and
we can say for our own emerging centre that they have contributed very
significantly and I know that there are other centres that probably wouldn’t exist,
but for this support. So that’s just another aspect of their patronage and support
that I would like to point out.
Raeburn: My comment is to say that the Cystic Fibrosis Research Trust, as it
then was, often cross-subsidized quite a lot of other things. Thus, much genetic
research money went to St Mary’s [Hospital, London]; that team may not have
found the CF gene, but it certainly did a lot of the background genetic work,
and CFRT [Cystic Fibrosis Research Trust] support led them to find the
Duchenne muscular dystrophy gene.97 The CF grant didn’t benefit people with
cystic fibrosis directly, but I think we have to accept that this cross-subsidization
is going to happen. 
Another comment: Ron Tucker. We need to realize that much developed
through the friendship of Joe Levy and Ron Tucker. Ron was a man who had set
up an immense network of friends; he realized that the strength of the Cystic
Fibrosis Research Trust was due to its links with and networks throughout the
country. If people didn’t know about cystic fibrosis out in the back of beyond,
Inverness or places like that, then CF centres weren’t going to work. I used to
abbreviate some of my slides CFRT and a little old lady in Scotland thought that
it really stood for CF Ron Tucker!
I think somebody ought to try to capture the image of this man whose
personality was large, his body was large. I don’t know about the other people he
used to see, but I was terrified when Ron phoned me up, because I knew he was
going to give me work to do, and I knew it was probably going to be a talk
somewhere. I knew, too, that in the hours after my talk I was going to have what
I said dissected by Ron, phrase by phrase, just to get right what was the
politically correct and patient-correct comment to make. I do hope that in your
history you are going to somehow try to capture some of Ron’s charisma and the
music hall act that worked so well for the Trust. 
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Professor John Govan: Just a quick comment on Ron Tucker. I remember
travelling with Ron. Very often we were asked to do talks round branch
meetings, and I remember one occasion on the third night he said, ‘That was a
different talk from the one you gave last night.’ And I said, ‘Yes Ron, but your
introduction was also different’. And I remember another night at a meeting in
Perthshire, ‘There’s not a lot in the audience, John, tonight. But just wait until
the bus arrives with the folk from the Dunkeld branch.’
Walker-Smith: And now the focus is towards research. There were considerable
advances during the period that we are looking at. I would like to ask Professor
John Widdicombe to introduce the general notion of basic research into cystic
fibrosis. This is a rather general topic, but he is very well placed to introduce it.
Widdicombe: It’s a pleasure to be here, although I think I may be here under
false pretences for two reasons: first, I have done no research at all on cystic
fibrosis, but the person who has done a lot of important research on CF is my
son, who works in the University of California, Davis, Sacramento, so you may
be confusing me with him, in which case I am very flattered.98 The second point
is that I was on the CF Research Trust a long time ago, in the 1970s and early
1980s, and what struck me then was that they were greatly supporting clinical
research, and we have learnt a lot about that and it was very commendable and
productive, but they also supported a lot of basic research. That was also a great
stimulant to basic scientists working on mucus and mucous membranes in the
UK, and it stopped many of us going off to the USA. We stayed put. I think that
was a very valuable task that the Trust carried out. 
As a basic scientist on the Trust, I sometimes felt that I was a lay member
compared with the clinical members, but I learnt a lot from listening to them.
In the 1980s, as you have heard already, there was a tremendous expansion of
treatment of patients with CF and prolongation of their lives, and at the same
time there was a great expansion of research on the basic mechanisms of CF.
However, probably the two aspects of study didn’t relate very much to each other
because, although the basic understanding of mucosal physiology expanded
enormously, it couldn’t very easily be applied to the disease. This application only
came about in the late 1990s, in the last few years, but the foundations were laid
in the 1980s. Before that, it was recognized that CF was a disease of mucus, both
in its original name, mucoviscidosis, and the fact that patients were coughing up
these large amounts of very unpleasant high-viscosity mucus. 
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But there were two problems in studying the disease in patients. One was that
almost inevitably the mucus was from infected and inflamed lungs, and the
infection and the inflammation changed its properties far more than the actual
disease itself. The more recent studies on CF mucus, which have been on
unadulterated mucus, suggest that the actual chemical composition of the mucus
is not very different in CF patients compared with normals. There may be some
differences, but they are minor ones, and the main difference occurs when the
mucus gets infected. 
The other problem about studying mucus, which applied not only in the 1980s
but continues through to today, is that nobody has yet discovered a way of
measuring mucus flow or output. You can collect mucus in a sputum cup, but that
is extremely inaccurate and not very scientific. Airway mucus must be about the
only body fluid for which no one has yet thought of a way of measuring its flow
rate. That seems to me to be a tremendous gap, not just in CF but in other
conditions such as chronic bronchitis, where one needs to have a good quantitative
method to study it. So if you look at the analyses of mucus in the early 1980s and
even before, in the 1970s and 1960s, the values are all over the place, including the
viscosity measurements, the ion contents, whether or not there are lots of lipids
present and so on. All the publications then, of which there are probably a dozen
or more, show enormous variation and don’t really make sense.99
Then in the 1980s, the position began to change. The formative paper was
published by Kilburn in 1968100 and most people working on mucus quote that.
He didn’t make any measurements, but he deduced that deep in the airways you
have a tremendous production of mucus, probably several litres per day, but by
the time it gets up to the trachea has been reduced to a very small amount. It’s
not been very accurately measured,101 but we know it’s a small amount, so
something must be happening between the small airways and the trachea to
absorb the bulk of this liquid coming up the airways. This was the paper that
stimulated research and interest into how the epithelium transports water and
sodium and chloride. 
I am going on to say a bit more about that in a moment but, in passing, one of
the big mysteries about mucus and airway fluid absorption is that although we
now know how mucus can be dried out, how liquid can be taken up in the
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airways, nobody has yet discovered what happens to the mucus glycoproteins;
you have an enormous bulk coming up from the small airways, and if they were
to get to the trachea, then the trachea would be filled with a very adhesive glue,
so there must be a different transport mechanism for glycoproteins that has yet
to be sorted out. 
But in the 1980s two things happened. One was there were many studies on the
physiology of mucus secretion; various models were prepared which showed how
it was controlled by nerves, by inflammatory mediators and by chemicals, and
the chemical composition of the mucus, and I was happy to be involved in some
of that research.102 It gave us a tremendous background or understanding of the
secretion of mucus. But even more striking, and I think more relevant to this
group, is the development of studies on ion transport systems through the airway
epithelium and their relevance to CF. This came about, partly as always, through
methodology; people began to set up epithelial preparations in Ussing chambers
and measured ion transport and water transport.103 Now you can’t easily do that
for CF, because you need quite a big specimen of airway mucosa. There have
been some studies taking airway specimens from CF patients who were having
transplants, and these you can set up in Ussing chambers, but obviously the
scope is very limited.104 But the second major advance was the use of extracted
epithelial and glandular cells to allow growth into confluent cell sheets, and to
study their properties, and that can be done from CF patients.105 Oddly enough
you can take them from somebody who has died of CF even up to 24 hours
before, and if you nourish the cells properly they will grow into an intact sheet
and you can study the way that CF epithelium behaves. So that was a
tremendous advance that came along in the late 1980s. 
The studies on epithelial transport have been conducted all around the world,
and there are dozens of names. The main groups include that of Boucher and
Knowles, and their colleagues in North Carolina, whose work I am sure you all
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know.106 I would like to think that the younger Widdicombe contributed quite
a lot to the study as well, but I mustn’t blow the family trumpet.107 It has led to
a comprehensive picture of what takes place in the CF epithelium compared
with normal; there are various ideas as to how this may apply, but essentially the
concept is that the chloride output into the lumen is decreased, because the
cystic fibrosis transmembrane regulator (CFTR) receptor is either blocked or
absent, probably blocked, so the chloride can’t be secreted. The sodium is taken
up more readily from the lumen into the tissues, and the reason for this is not
quite clear; it’s quite possible that the CFTR inhibits sodium uptake so that if
you get rid of CFTR then sodium uptake is increased. But the net effect is
perfectly clear, you have less chloride and less sodium in the airway lumen, and
as a result you get less water, because water follows the salts. So the airway mucus
is decreased in concentration and the mucus is dehydrated. This is thought to be
the underlying basic mechanism that causes the mucus changes in CF. 
There are a lot of controversies and gaps in this description still. Boucher has been
suggesting recently that there are two possible mechanisms, one where the mucus and
the liquid in the airways are kept isotonic, and the other where it’s hypotonic, and
there’s a lot of argument about this.108 But the fact that the ion pumps can change the
behaviour and the adhesiveness of the mucus seems to be well established, and to be
a fundamental mechanism to explain why CF airways behave abnormally. 
Professor Alan Cuthbert: I would like to make two comments about what John
Widdicombe has just said, one in relation to organs like the airways that produce
a lot of mucus, and a second comment about another organ that produces no
mucus at all, but is also affected in CF, namely the sweat gland. To start with the
airways, I think if you look at where the product of the CF gene is found in the
airways, it’s found in the superficial epithelial cells of the large airways, but the
major contribution, or the main concentration of CFTR, the protein which is
coded for by the CF gene, is found in the cells at the bottom of the mucus
glands. There is quite a lot of evidence that these glands secrete bicarbonate, and
if that bicarbonate can reach the surface of the airway epithelia, being slightly
alkaline, it reduces the mucus viscosity. 
So what I am really saying is not only may mucus viscosity be increased in CF,
as John [Widdicombe] was describing, but that while clearance is very much
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impaired by the withdrawal of water, viscosity may also be increased because of
a lack of a suitable pH. With regard to what’s going on in the large airways, I
think there are quite a lot of people who would support the postulate that the
major function of CFTR in the airways themselves is to downregulate ENaC,
epithelial sodium channels. There is a three- to four-fold increase in sodium
absorption in CF airways compared with normal, this is also an enormous
contributory factor to the concentration of all those substances which are not
only making it difficult for the CF patient, but making access of drugs given via
aerosols or when considering giving gene therapy by an airway route, this is a
barrier to getting into those positions. 
But I wanted to say something else about the sweat gland and to pose a
philosophical question. The question is ‘Would we have been better off never
having had the sweat test?’ Thirty years ago physiologists knew how salt secretion
in the sweat gland was controlled. Salt was secreted into the proximal coil of the
sweat gland as an isotonic fluid and, as it moved into the reabsorptive coil, it was
reabsorbed leaving you with relatively hypotonic fluid on the surface, which we
call perspiration or sweat. It was also known that that process was driven by the
active reabsorption of sodium, chloride followed passively, and because that part
of the sweat gland is not permeable to water, the water ended up on the surface
of the skin. So it was a sodium-led process. 
Now when it was found, by di Sant’Agnese and others, that the salt content of
the sweat was high in CF109 and since the process of salt absorption in the
reabsorptive duct was sodium-led, this led to the postulate that there was a defect
in the absorption of sodium which was responsible for CF. About 30 years ago I
looked at the CF field, wondering whether I should move into it, and decided
not to because it was in a right mess, the reason being people were collecting
saliva, urine and sweat from CF patients and looking for things within these
fluids that inhibited salt absorption. I think one of the greatest discoveries,
particularly seen in hindsight, was that of Paul Quinton who, in 1983, published
a paper where he used the perfused human sweat gland and found that if you
perfused it with a solution without any chloride, you produced basically a sweat
gland with all the properties of a CF sweat gland.110 That was the first indication
that it wasn’t really the cation, although the cation was actively transported, it was
the failure of the anion to be able to move with the cation that was the cause of
CF. And as many of you know, Paul Quinton, who is now about 60, is himself a
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CF patient, and if you visit him or his lab and you look at the inside of his
forearms, they are covered with little scars where he’s donated so many skin
biopsies for all his experiments over the years, that he is permanently marked by
these. But it was he who pointed to the fact that the protein coded for by the CF
gene was maybe something to do with chloride and, of course, we know now that
the CF gene does indeed code for an epithelial chloride channel.111 I think that was
a very early formative influence on how basic research has gone since that time.
Widdicombe: I can give you another reason why the secretion of sweat is not a
good analogy of secretion of airway liquid or mucus, and that is that, as you
explained, in sweat you normally end up with a hypotonic excretion because of
the absorption of sodium and chloride following it. Whereas most of the
evidence on the tonicity of airway secretions suggests that they are either isotonic
or slightly hypotonic because the airway epithelium is so permeable to water that
it flows through readily to follow the sodium and chloride concentrations, the
sweat glands are quite different. 
I am sure you are right about the submucosal glands being the most important site of
the abnormal secretion of the airways in cystic fibrosis. This leads me to a comment
that I was going to make later, and that is the use of a mouse model. The mouse is a
model beloved by geneticists for very good reasons. It’s rather like the guinea-pig for
pharmacologists; pharmacologists love the guinea-pig because every time you ask it a
question it says ‘yes’, and you publish a paper. It’s the most compliant of species for
pharmacology and, of course, the mouse is the same for genetics. 
But the problem with using the mouse for CF studies is that it has virtually no
submucosal glands.112 It also has almost no goblet or serous cells in the
epithelium if it’s healthy; if it’s airways get diseased and inflamed, you get some
mucus cells appearing in the bronchi. The number of CFTR receptors in the
mouse is far smaller than in most other mammalian species, which is
understandable if they haven’t got much mucus secretion tissues. So the mouse
is fine for genetics, but if you move on to study the physiology of mucus
secretion, I think it is probably a very poor model.
Walker-Smith: I think that leads us logically on to another aspect of research,
which is more focused, namely microbiology. Professor John Govan is going to
introduce the topic. 
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Govan: What is microbiology? I actually started off as an organic chemist. The reason
I say that is that when I went to work in a lab my boss was obsessed with the idea of
what a chemist does and kept asking questions like, ‘Is this stuff stable at 4o C, John,
can I fridge it?’ It’s the same with microbiology. Not always as straightforward as it
seems. Consider the germ that causes cholera. Things are fairly straightforward. Most
microbiologists will tell you that the Vibrio cholerae is attracted to mucin lining the
human gut, indeed the bug swims towards it, penetrates the mucosal blanket and
then delivers its toxin. Well, P. aeruginosa is also attracted to mucin lining the gut and
airways – that’s the way we get rid of it. The mucin is moved up the airways and taken
away by mucociliary clearance. So why do we have problems in cystic fibrosis? It’s a
complex story, and I hope I am not breaking the rules by giving you a handout with
illustrations (includes Figures 4–8 below).
This is a difficult job. I remember listening to Margaret Mearns many years ago,
saying that there are people who use slides, and there are people who have
something to say, so the natural thing is not to use slides, and I have never
forgotten that. Duncan Geddes, whom I respect very much and always try to
follow, says that there are lots of grey areas in microbiology. So these are black
and white but I have the colour versions as well. It was just to try to give you
some pictorial thoughts as we go through the microbiology. The theme is that
there are many aspects to it. 
We have heard of the original work of Paul di Sant’Agnese and I thought we
should start off by looking at the very strange spectrum of pathogens in CF. To
a microbiologist this is very unusual. The first illustration is the table by di
Sant’Agnese in 1945 describing the aerosolized use of penicillin (Figure 4).113 At
that time there were 14 post mortems, no less than 12 due to Staphylococcus
aureus. For people who say that Haemophilus and Pseudomonas were not around
at that time, if you look carefully, Haemophilus influenzae non-capsulate type B
is there, and for people who say microbiologists keep changing names, because
we can’t pronounce them or we can’t remember them, note Bacillus pyocyaneus is
there in the third patient from the bottom. B. pyocyaneus was the original name
for P. aeruginosa, so name changing isn’t something that only happens now. 
This was the pre-antibiotic era and there’s absolutely no doubt that antibiotics
have made a major impression. However, the use of antibiotics in cystic fibrosis
is an art and has been described by Stutman and Marks as a science unto itself.114
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Why is that? Well, when Alexander Fleming discovered antibiotics, even he
didn’t look at the therapeutic value. He was more interested in cultivating his
beloved Haemophilus. I am sure that today he would be asked about the
intellectual property rights and the patent. Many clinicians and many
microbiologists think of antibiotic sensitivity as the zone of antibiotic attacking
organisms, growing in a totally artificial environment in the lab. Historically, the
antibiotic ciprofloxacin was the first antipseudomonal agent available in oral
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Figure 4: Post-mortem cultures – cystic fibrosis of the pancreas. January 1939 to June 1945.
Table provided by Professor John Govan, 2002.Adapted from di Sant’Agnese and Andersen (1946):
21. 1946 © American Medical Association.All rights reserved.Reproduced with permission.
Case Age Lung
no. (months) Predominating organism Also present Other organs
S2 4 Haemolytic Staph. aureus A few Pneumococci, type 14 Trachea:
Staph. only
S3 21/2 Pneumococcus, type 25 Many haemolytic Staph. aureus;
a few nonhaemolytic Staph. albus
S8 15 Haemolytic Staph. aureus Moderate number
(m+c+) Haemophilus influenzae
(not B)
S10 4 Haemolytic Staph. aureus
(m+c+)
S15 4 Haemolytic Staph. aureus Haemolytic Strep. a few
(m+c+)
S16 15 Haemolytic Staph. aureus Haemolytic Strep. Bronchus: Staph.
(m+c+) and Strep.
S18 11 Haemolytic Staph. aureus
(m+c+)
S19 15 Haemolytic Staph. aureus
(m+c+)
S20 2 Haemolytic Staph. aureus Ear: Staph.
(m+c+) aureus (m+c+);
a few B. coli
S23 12 No culture. Microscopic
examination: clumps of
Gram-positive cocci,
morphologically staphylococci
S25 32 Haemolytic Staph. aureus B. pyocyaneus
(m+c+)
S30 9 Haemolytic Staph. aureus A few Strep. viridaos, B. coli
(m+c-)
S33 1 No growth
S37 40 Haemolytic Staph. aureus Trachea: Staph.
(12) (m+c+) aureus (m+c+):
a few 
diphtheroids
M+ C+ = Mannitol fermenting and coagulase positive
formulation. I don’t know if Sandy Raeburn was there but certainly Morrice
McCrae was, and I was taken by Bayer to Leverkeusen, Germany,115 in the early
1980s and asked, ‘What do you think of an oral anti-Pseudomonas agent?’ and I
thought, ‘Wonderful – CF kids can go to summer camps and have jobs’. Of
course, at that time we had little cross-infection and we didn’t realize that the
hazards of summer camps would come back with a vengeance later on. 
The point I want to make is that although antibiotics do have lots of benefits in
cystic fibrosis, they have to be looked at in a very different way to that in which
antibiotics are used elsewhere. I am thinking particularly of urinary tract
infections. In contrast to the high concentrations achievable in the bladder the
levels we can achieve even with the very best anti-Pseudomonas antibiotics today
are only barely reaching the killing levels. What do we mean by sensitive and
resistance? How can we use antibiotics best? Clinical trials are enormously
expensive. This is another very, very grey area. 
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Figure 5: (a) The Doggett legacy – mucoid alginate-producing Pseudomonas in cystic fibrosis.
Govan and Harris (1986). 1986 © Blackwell. Reproduced with permission. (b) Gram-stained
sputum from a patient with cystic fibrosis harbouring mucoid P. aeruginosa.The bacteria can be
seen in a gelatinous microcolony (M), which is attached to the bronchial mucosa (BM) and is
significantly larger than the adjacent phagocyte (P). Govan and Glass (1990): 22. 1990 ©
Longman Group UK Ltd. Reproduced with permission. Photographs provided by Professor
John Govan, 2002.
a.
b.
The next illustration (Figure 5) that I want to remind you of, since this is
historical, is about the work of a man who does not get the kudos he deserves.
Bob Doggett was a larger-than-life Texan, who, in the early 1960s, pointed to a
number of important aspects of CF microbiology. We often talk of Americans
rediscovering the wheel. However, Doggett made many observations, which are
still true today. For example, the important link between not only Pseudomonas
but mucoid alginate-producing Pseudomonas in CF, and the fact that these
organisms are highly unstable in the laboratory, very difficult to maintain, and
yet are very stable in the CF lung, indicating the role of selective pressure. 
Well, why is the CF spectrum of pathogens so strange? Why is Pseudomonas so
dominant? The clue is the photograph on the left (Figure 5a). We heard Mary Dodd
talking earlier about the use of seaweeds and iodine. This material you see being
lifted up by the glass rod is alginate – the polysaccharide from mucoid Pseudomonas.
It’s a major constituent of seaweed, giving it its flexibility and strength to stick to
stones and avoid being flushed away by the waves. Alginate is also in Flora
margarine, it’s in ice cream, it’s in fruit and flavoured milk drinks, and it’s also the
E40 additive to Carlsberg lager. So, in CF, we have a very unusual polysaccharide
and a pathogen, which having got into the mucosal barrier are not moved away.
Pseudomonas alginate is also a beautiful gelling agent. Far better than seaweed
alginate. It gels exquisitely in the presence of calcium. So, with the raised calcium
concentration in the CF lung, the alginate from the organism, the DNA from the
neutrophils and the mucosal blanket, you have a highly protective bacterial biofilm. 
In the 1970s we introduced the term ‘frustrated phagocytosis’ to describe the
protective effects of the biofilm. One thing that you do not want in the lung is
a phagocytic neutrophil coming to the site of infection with its armoury and
being frustrated. So we have a chronic infection and a very difficult kind of
infection. I think the dominance of Pseudomonas in CF is because very few other
bacterial pathogens can put these bits and pieces together to colonize the lung. 
What is the lesson from this? Enormous amounts of work have been done on
alginate genetics. This is how I came into CF as an MRC Travelling Research
Fellow in Australia. The major impact of genetic studies is the justification for
going in with early aggressive antipseudomonal therapy to prevent the emergence
of mucoid mutants. This is probably one of the major therapeutic advances of the
1980s, thanks to Jim Littlewood, and Niels Høiby and his group in Denmark.116
By the 1990s, we were aware that there were many individual strains of these
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microbial pathogens. However, cross-infection was not really a problem. People
with CF would get their own Pseudomonas, keep it for life and, although camps
were being encouraged and people were mixing, unlike in haematology wards and
in burn wards, cross-infection was not a problem. Why not? 
Perhaps Pseudomonas was becoming such a parasite in the lung that it was losing
its ability to spread. That all changed in the late 1980s and 1990s, when we were
faced with a new CF pathogen from the soil. Although many people are aware
nowadays of previously sensitive, pathogenic organisms becoming resistant – for
example, methicillin-resistant Staphylococcus aureus [MRSA]117 – I want to warn
you about another development, and that is naturally resistant organisms from
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Figure 6: Epidemic spread, cross-infection control and genomic fingerprinting.
Unpublished photograph provided by Professor John Govan, 2002.
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the soil acquiring virulence. The paradigm of this development is the organism
that we know as B. cepacia. In the 1990s, we had evidence that it was spreading
in Edinburgh and Manchester, and between other centres (see Figure 6a). Such
spread had enormous implications for cross-infection control and multicentre
collaboration. We also had important developments in genomic fingerprinting
of bacterial pathogens. Somebody mentioned earlier about patients falling in
love. I remember when we were looking at the Edinburgh epidemic, noting
evidence for cross-infection outside the clinic through social contacts. What were
patients getting up to socially? In this histogram, patient 7 was described as a
flirtatious Scotsman. What does that conjure up in terms of social contacts at
summer camps? 
I want to just introduce the idea of interdisciplinary bridging. Is there life after
Pseudomonas? Is there life after Burkholderia? The organisms that I think we are
going to see in cystic fibrosis now and in the future are really quite challenging.
Think of the genome size of Burkholderia to scale. It’s three to four times bigger
than Haemophilus influenzae, twice as big as E. coli (Escherichia coli ) – an
enormous genome. This organism is not just resistant, but can actually use the
the antibiotic, penicillin, as its sole nutrient. This isn’t just resistance, this is
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Figure 7: Emerging cystic fibrosis pathogens – Thoracic Park. Unpublished photograph provided
by Professor John Govan, 2002.
thumbing its nose to clinicians and microbiologists. And why do we need
interdisciplinary bridges? This is a wonderfully adaptable organism. It’s so
metabolically active, it can break down the noxious herbicide, Agent Orange.
You can use it to decontaminate soil in the preparation of golf courses, you can
use Burkholderia to decontaminate water reservoirs. There’s a lot of interest in
using its antifungal properties to protect crops against fungal diseases. It’s better
than the best herbicides available. It’s also a wonderful soil fertilizer, reducing the
need for nitrogen fertilization by 20 per cent. 
So we have a problem. How do you tell the good bacteria from the bad ones?
This is a major challenge to microbiologists and clinicians today in CF. The more
we know about organisms, the more we can try to tailor infection control to the
organism’s behaviour and what the patient will accept. B. cepacia is a good
example of the increasing problem of name changes and pronunciation. You
can’t think of microbiology now without thinking of these ‘Thoracic Parkers’, as
Stuart Elborn calls Stenotrophomonas maltophilia (Figure 7). These are natural
organisms of the environment, what they do have in common is that they are all
multidrug  resistant. We have isolated them with more frequency now in CF. I
think because of more aggressive therapy. It doesn’t mean to say they are all
clinically relevant.
We are never going to be able to avoid the challenge altogether of multidrug-
resistant bacteria. That is evident from the most recent survey in the UK, which
showed that there are more resistant strains among the CF population than there
are in the Pseudomonas population outside CF. Fortunately, when Paul di
Sant’Agnese was using penicillin in CF, acquired resistance was not in the
microbiological repertoire. I can’t mention Paul di Sant’Agnese without sharing
an experience that occurred early in my career.
I remember as a young microbiologist at a CF meeting in Brighton in 1984,
standing by my poster and being aware that the great man was around. I went
behind a counter to get a drink of water. The door opened and this man came
in looking like something out of the Mafia, long dark coat and a hat, ‘Are the
lunches being served?’ he asked. I looked at him and said, ‘Well, I don’t know,
Dr di Sant’Agnese,’ because I recognized him from a photograph. I saw these
British Airways lunch packs under the counter, gave one to Dr di Sant’Agnese,
and one to his friend. I then walked back to my poster. The American at the
poster next to me said, ‘You’ve done it now, John, you are in deep trouble’. I said,
‘What’s wrong?’. He said, ‘Protocol! The Royal Party are about to come round
and this pair of men are sitting having their lunch and you gave it to them.’ 
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Walker-Smith: It is very interesting historically that the presence of bacterial
organisms in the soil at the end of the nineteenth century was widely believed to
be important for human disease. Investigators were measuring soil
temperature.118 Sir George Newman, Medical Officer of Health in Finsbury,
London, used actually to go out into parts of London to measure soil
temperature. He observed that when the soil temperature rose there was an
increased risk of infantile diarrhoea and mortality.119 So it is a fascinating
concept, organisms from the soil.
Govan: I think what the Burkholderia story has done is force us to make bridges
with the soil microbiologists. We now have an international working party,
which the CF Trust supports.120 The International B. cepacia Working Group
started with six of us; now 60 people are involved with input from soil
microbiologists who hope to learn from us, and vice versa. I think we have got a
lot to learn from the way organisms behave in the soil and the way plants protect
themselves. It’s a big topic. 
Littlewood: Could I just ask about these plants and soil? The Lancet this week
has got rather a disturbing paper on quite a few isolations of B. cepacia from soil
specimens.121 Is that something new? I know you get it from soil, but it looked
to be a lot.
Govan: It is surprisingly difficult to prove that CF individuals acquire bacterial
pathogens like Burkholderia from the soil. However, genomic fingerprinting
shows that in some cases isolates from the soil and from patients are clonal. The
other evidence is that we also had a large outbreak of sheep infection with the
same Burkholderia that are causing problems in CF. I am concerned, but there
are some rogue strains that are adapting to the human population. 
Walker-Smith: That paper suggests that the human pathogenic strains are not
necessarily distinct from environmental strains, which is remarkable. 
Govan: I agree. The US Environmental Protection Agency had a meeting 
in 1999 to discuss the human hazards of Burkholderia biopesticides. Recent
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proposed legislation suggests that licensing of new biopesticides will 
be difficult.122
Littlewood: It does explain sporadic instances though, doesn’t this?
Govan: Yes. It means that no matter how far you take segregation down the line
you will always expect sporadic cases from the environment. But the
Burkholderia in the environment may not all be harmful.
Raeburn: If you look at the microbiology of CF over the last 60 years, it’s gone
through the Staphylococcus stage, the Haemophilus stage, and so on, and John
[Govan] has brought us up to date. There was a lot of uncertainty in the late 1960s,
early 1970s, about what were really the important organisms that might be
destroying lung tissue. I think it’s worth mentioning David Lawson again, whom
Archie Norman mentioned;123 working with David was a laboratory scientist,
Barry Saggers, who was doing measurements of precipitins, Haemophilus
influenzae, Staph and later on Pseudomonas (although it was Niels Høiby who took
that on). What their data seemed to show was that first there was Haemophilus in
very small quantities, then Staph, and later on the Pseudomonas. The story of cystic
fibrosis has also the story of clinical immunology interwoven with it, because how
did you know that the particular bacteria you were finding in the sputum were
likely to be pathogens? I recall great, furious arguments and discussions with,
among others, David Lawson, as we tried to work out what was the best treatment.
Dodge: Going back to John Govan’s first illustration (Figure 4), I was interested
in the age at which the autopsies were carried out, because the age is in months,
and the only one who had Pseudomonas (or B. pyocyanea as it was called) was 32
months old. They weren’t living long enough to acquire Pseudomonas, they were
dying from their first infection, which was Staphylococcus aureus in those days, and
I think that’s a measure of what we have seen in terms of shifting microbiology.
Govan: I think we should expect the microbiology to evolve, because the CF
population is not the same and the immunology is not the same. The one constant
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factor in this is the expectation that microbiolgists will provide black-and-white
answers. In the biopesticide argument, both sides started off friendly. Then we got
labelled as so-called ‘medical microbiologists’. They said Burkholderia biopesticides
do not fulfil Koch’s postulates and so are harmless.124 In reality it is difficult to show
that any pathogen in CF fulfils these historical postulates. When I came back from
Australia in 1975, and I went to my first CF meeting, they said Staph. aureus is the
pathogen, and Pseudomonas is a marker of CF lung disease. I just about gave up.
Then B. cepacia arrived and again this was considered to be just a marker. It wasn’t
really a pathogen. The problem is that these organisms are parasites in the CF lung.
As Sandy said, it’s the immune response that’s really doing the damage. The
bacteria are just surviving and provoking a damaging immune response. They are
not toxigenic pathogens like the cholera ones.
Farrell: In the spirit of the question you posed about what was it like at the time,
and why things happened in the way that they did, I want to emphasize a point
about P. aeruginosa and its pathogenicity. I started in this field in the late 1960s,
and at that time there was a raging debate about whether or not P. aeruginosa was
a respiratory pathogen.125 I remember when I joined Paul di Sant’Agnese in 1972
that he did not believe it was a pathogen until we began to treat his patients with
gentamicin, and a dramatic response to this aminoglycoside, a relatively new
antibiotic then, convinced him. So I really do think what happened with regard
to the importance of P. aeruginosa came about because of the observations of
clinicians about the dramatic response to antibiotic therapy, just like the
penicillin response to Staph. aureus, that is history repeating itself.126
Littlewood: I think it’s also Høiby’s work on crossed immunoelectrophoresis and
antibodies, correlating it with the clinical condition, wasn’t it in 1977?127
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Super: I wanted to give credit to our microbiologist, Fraser Williams, in
Manchester, who at the end of the 1970s or in the early 1980s was already
reporting his Pseudomonas as rough, smooth or mucoid.128 There is no doubt
about the increased pathogenicity of the mucoid variety and lots and lots of
places have been catching up with what he was doing in helping us with our
patients for years. 
Walker-Smith: We had better move on now and come to Dr Maurice Super to
talk on the huge subject, the search for the gene. Would you like to give us some
comments about that, introducing the subject for us?
Super: Unlike haemoglobin, the gene product of cystic fibrosis was unknown.
Therefore indirect methods were needed to find it, the so-called reverse genetics.
Eiberg in Denmark in 1986 studied the polymorphic enzyme paraoxonase,129
which occurs in two normal forms in almost equal proportions. He found that
affected siblings shared the same form 90 per cent of the time and they might
have inherited either form from their parents. The odds were about 10 000:1
that paraoxonase and the cystic fibrosis gene were linked. No one knew the
chromosome localization of paraoxonase. John Edwards from Oxford presented
a negative gene map at the Human Genome Conference in 1984.130 In other
words, a summary of publications of similar experiments to those that Eiberg
had done, but which had been negative. Lap-Chi Tsui in Toronto used this
negative map and he concentrated on the least-studied regions, and in a very
short time, in fact later the same year, in 1985, he had already localized the cystic
fibrosis gene to the long arm of chromosome 7.131 The marker that he discovered
was further away from CF than paraoxonase, but there had been other recently
discovered lengths of DNA known to be on the long arm of chromosome 7. 
One notable one was called the Met oncogene and there was another one from
Professor Bob Williamson’s lab at St Mary’s Hospital Medical School, London,
which was called pJ3.11 and these were found to be sitting almost on top of the
cystic fibrosis gene.132 It was in the nature of Bob Williamson to share this
information very quickly with clinicians throughout the UK. We, for instance,
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had been more or less expecting this discovery to be made, and had been storing
samples from our patients with cystic fibrosis and their parents for about two
years when the discovery was made. Immediately very accurate prenatal
diagnosis became possible and also carrier detection in the siblings of the person
with cystic fibrosis. 
The search for the CF gene itself was now on in earnest. Unfortunately, the St
Mary’s team were held up by a false dawn. So between 1986 and 1989, there was
a publication on a gene called CS 7 with Estivill as the main author,
133 he was
working with Bob Williamson at the same time. They thought that they had
discovered the cystic fibrosis gene, except as I said this was a false dawn. Francis
Collins from the USA realized that Lap-Chi Tsui was a name to follow and he
set up a collaboration with Lap-Chi Tsui and also their brilliant biochemist, John
Riordan, and he introduced a technique called gene jumping, rather than gene
walking. Gene jumping is a catchy title, but in actual fact it meant you threw a
type of DNA lassoo along the gene and you skipped over a certain part but it
could stick to a part in a place of relevance.134 And by doing that they discovered
an open reading frame rich in GC [guanine and cytosine] bases, which looked
very much like a gene. Not only that, they also discovered that this particular
open reading frame expressed itself all the way down through species, down as
far as the chicken. 
So in other words it sounded as if this had the characteristics of a gene. There
were classic publications in Science in September 1989 where the structure of the
cystic fibrosis gene was elucidated by Lap-Chi Tsui, John Riordan and Francis
Collins,135 showing the structure of the gene and also showing the major
mutation, delta F508. John Riordan, a brilliant chemist, did expression studies,
and I think the reason why we were beaten to the discovery of the CF gene was
the fact that they were more advanced in their studies of expression of what they
found. It is sad fact that we were sent a probe from Bob Williamson’s lab to test
against our panel of cystic fibrosis patients and we found, ‘Yes, yes, it’s very good,
it’s just as good as KM19 and XVC2,’ which had been discovered, and that were
extremely close to the CF gene. It is sad that the particular probe that we had
been sent by Michelle Ramsey from Bob Williamson’s lab was in the cystic
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fibrosis gene, but no one realized that they had actually discovered the cystic
fibrosis gene, because unfortunately their expression studies were not as
powerfully developed. John Riordan, in one of the classic papers, published a
hydropathy plot looking at the amino acids, and showing which ones were
hydrophobic and which ones were hydrophilic. This allowed him to propose a
model for CFTR, with two trans-membrane domains, two nucleotide binding
folds and a large R domain, sometimes called the ‘Riordan domain’.136
This model from 1989 has stood the test of time and has helped us towards a basic
understanding of pathophysiology and hopefully to the development of new
treatments based on the knowledge of the structure of the CF gene, and also gene
replacement treatment. So these things are on the go, although unfortunately they
are in their infancy and have not been successful yet. Delta F508 in the Canadian
and American population was found in about 67 per cent of CF genes.137 This
knowledge shot round the world and within days we were able to test our
populations in many, many places. We found that in Britain the delta F508 is 75
per cent, in the Manchester area it was 81 per cent, and in some parts of Scotland
it’s 84 per cent.138 There were other publications from Europe that showed a cline,
in other words a genetic incline plane showing that delta F frequency rose the
further north and west you moved in Europe. So at the time Denmark – and I
think it still does – holds pride of place with 88 per cent of delta F508.
Further mutations of the CF gene were discovered quickly and Lap-Chi Tsui
formed an international consortium of laboratories and centres to share their
information, done very successfully indeed by e-mail. Currently, more than 1000
cystic fibrosis mutations have been described, although fortunately only 20 of
them reached any significant proportion. I have looked in the programme to see
where this is going to be dealt with and I don’t think it is, so if I could be
permitted a little bit of genotype–phenotype conversation: obviously the next
big thing was how this would correlate with the clinical picture in our patients. 
The original publication spoke about those who are homozygous for delta F508,
which was about 45 per cent of their population, who were pancreatic
insufficient, and those who were heterozygous, either with delta F and another
mutation or with two different mutations, who were either pancreatic sufficient
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or pancreatic insufficient. They used the terms ‘severe’ and ‘mild’ mutations.
There is some truth that when there is pancreatic sufficiency the disease may be
milder in certain respects, but I think adult physicians are rather offended now
by the term ‘mild’, because the lung disease need not necessarily be mild at all.
Nevertheless, a lot of the patients who had delta F and another mutation had
very late diagnoses, so the diagnosis was more subtle. Obviously, if there is
pancreatic sufficiency one might not think of the diagnosis of CF that quickly.
Other than pancreatic sufficiency and insufficiency, knowing the actual
mutation was a poor guide as to what would actually happen in your patient,
with one or two small exceptions. For instance there’s a Celtic gene called
G551D, which has a negative correlation with meconium ileus. This was realized
by Brandon Wainwright from Australia, who also worked in Bob Williamson’s
lab at one stage. He engineered a G551D cystic fibrosis mouse that did not die
of intestinal disease as most other cystic fibrosis mice did.139 In other respects
genotype–phenotype correlation generally was poor. We thought that G542X
had a positive correlation with meconium ileus – which was also so in Toronto
– it’s the second commonest mutation in Spain and there’s no correlation
between G542X and meconium ileus in Spain. So there’s a lot that we don’t
understand completely. 
The last thing that I would say, is that knowing the actual genotype does not
allow you to say that the patient is going to be mildly affected, or that the patient
is going to be severely affected. Is there another gene, or are there other genes,
affecting the way that the cystic fibrosis gene works? In a collaboration study
looking at siblings born with meconium ileus and especially for siblings where
one was born with meconium ileus and the other was not, Lap-Chi Tsui and his
research workers looked for markers first in the cystic fibrosis mouse, in certain
mice that did not die of intestinal disease, and quickly found a gene on
chromosome 7 in the mouse, which seemed to be able to predict which ones
were going to survive.140 Chromosome 7 in the mouse turns out to be analogous
to chromosome 19 in the human, and they have extended that study to humans
with meconium ileus and have found indeed that you can predict from a gene
on chromosome 19 as to the likelihood of meconium ileus recurring in the
family. The actual gene on 19 hasn’t been discovered, and sadly no other gene
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has yet been discovered that might tell us about who’s going to get mild and
who’s going to get severe lung disease. 
Walker-Smith: Thank you very much, and that’s a very eloquent account of a
very complex area and we are very grateful for that. Who would like to make 
any comments?
Geddes: I would like to comment on Bob Williamson and the great gene race,
and the disappointment that was expressed before at the CF Trust at not being
the winners of the race. It’s probably not a fair way of looking at it, because the
contributions, which that money made to Bob’s lab, fertilized all the other work
as well, so the contribution was large. Also I wanted to point out the three other
major contributions that Bob made: he elevated the scientific level of RAMAC
by insisting on high scientific standards and getting away from a sort of more
anecdotal approach that had happened before, and then he attracted in a whole
lot of top scientists in a very generous way. As soon as anything happened, he
went out and talent-spotted and got people into the CF world, people like Alan
Cuthbert and Chris Higgins, who thought they went into the CF world out of
scientific interest, but actually Bob attracted them in telling them how important
it was, and he made a big contribution in that way. His third contribution was
that he was a fantastic enthusiast and used to attend branch meetings – he
probably raised at least as much money as he spent – and his contribution was
very large in the 1980s to the whole CF effort, for these reasons. 
Booth: May I strongly support those comments. 
Farrell: I think it would be important for everyone to know what initially
motivated Lap-Chi Tsui to do this research. This was because of Bob Williamson
and the conference that was sponsored in part by the CF Trust in Brighton in
1984. Lap-Chi told me last year or the year before at the European CF
Conference that he had gone to the previous conference at Padre Island, Texas,
sponsored by the National Institutes of Health and the US CF Foundation, and
he decided that the state of fundamental research in CF was disappointing – a
‘mess,’ as he described it to me. He came to Brighton and he found that the same
situation was evident, except for the paper presented by Bob Williamson, which
convinced him that the only way to figure this disease out, to get through this
‘mess’ of confusing information, was with a molecular genetics approach. So it
was that conference in Brighton sponsored by the CF Trust, that he regards as
being pivotal.
Walker-Smith: It shows how worthwhile a scientific meeting can be.
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Raeburn: One other thing about Bob Williamson is that he actively went out
and spoke to the branches of the CF Trust and explained in a very, very
understandable way what they were doing, and won the support of patients,
parents, and the other lay people.
Norman: As a side issue, if you like, Cedric Carter came to me in about 1974 and
said he had just heard a lecture from a very bright young man called Bob
Williamson. I was collecting speakers for a course on advanced medicine, and
wanted somebody on genetics. We got Bob Williamson to come. Immediately
afterwards we, Cedric and I, said to him, ‘What about getting interested in cystic
fibrosis?’ ‘Oh, I haven’t heard of that, and anyway I’m too tied up with renal
problems at the present.’ But he came back to us, and with the help, as usual, of Joe
Levy and the Trust, we enticed him to start a small department within his laboratory
[at St Mary’s Hospital, Paddington, London], for which the Trust increased the
funds four or five years later, so he was able to have a totally cystic fibrosis laboratory. 
Dodge: I just want to make one comment, which is that we should not forget
that cystic fibrosis isn’t only about genes and their modification. There was a
paper this year in American Journal of Respiratory Disease and Critical Care
Medicine, which said that the single biggest factor in determining the severity of
cystic fibrosis for anyone with a given genetic make-up was their socioeconomic
circumstances.141 I think that’s one of the factors that has contributed to the
increasing lifespan since the 1940s, when as Archie said, before we even had the
[National] Health Service, that improving socioeconomic conditions have, I am
sure, made quite a big contribution to the survival of patients.
Goodchild: You ask about diagnosis and the work at Birmingham. For me that
was from 1969 until 1974. I have taken ‘diagnosis’ in this context to mean
confirmatory investigations, following appropriate features by clinical history,
which would vary according to the age of the child, and characteristics on clinical
examination, including chest X-ray, cough swab or sputum culture for the so-
called ‘typical organisms’ – that is, for S. aureus, H. influenzae and E. coli in the
younger child, with P. aeruginosa, often of the mucoid type, in the older child. 
In those days, some 15 to 20 years before the recognition of the CF chromosome
in 1985 and the gene in 1989, confirmatory investigations consisted primarily
of sweat tests, at least two in number, carried out by pilocarpine iontophoresis,
usually on the forearm but sometimes on the back (in small babies), with the
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absorptive paper left in place for at least one hour.142 Prior to this, stool
microscopy on three occasions, under a regime of known and adequate fat
intake, was likely to have shown excessive numbers of fat globules and very low
values for chymotrypsin, or none at all. For patients with positive results by sweat
test and stool examination, this was usually considered sufficient for the
diagnosis of CF. I remember Geoff Brown working out a methodology for
detecting stool chymotrypsin in the laboratories at Birmingham.143
In the later years of these children, at any age from two or three years, an attempt
was often made to distinguish the pancreatic sufficient from the insufficient (and
we suspected even then, on clinical grounds, that it was likely that there were at
least two different types of CF). This distinction between the pancreatic
sufficient and insufficient was made by examination of a three- or five-day faecal
collection for fat content (although usually without markers), ideally under
conditions of known dietary intake, looking for fat absorption that was below 50
per cent. In this area, I think perhaps the laboratories were a little more
cooperative in the late 1960s and early 1970s than they are now! 
To return to the sweat test for a minute, values were positive if they were greater
than 60 mEq/l, for both sodium and chloride, with doubts raised and further
tests if sweat weights were less than 100mg, if electrolyte values for sodium and
chloride were between between 50 and 60 mEq/l, or if these measurements
differed from each other by more than 30 mEq/l. In babies of less than one year,
values greater than 40 mEq/l were regarded as suspicious. 
Equivocal results, for sweat tests in particular, required duodenal intubation for
pancreatic function tests, which was a considerable ordeal for the patient, not to
mention the attendants, taking several hours. Stomach and duodenum were
intubated separately but there was no provision at that time for the infusion of
a non-absorbable marker solution, via a third tube, situated approximately at the
Ampulla of Vater; this was a modification introduced later, in order to obtain a
more accurate measurement of fluid volume, produced during continuous
intravenous infusion with cholecystokin/secretin, in that order.144 Hormonal
stimulation was by sequential shots of intravenous pancreozymin and secretin in
that order. For the majority of CF patients, duodenal fluid was scanty in volume,
sticky in nature, with a pH of less than 7; enzymes and bicarbonate were present
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in negligible quantities, or undetected. In some 10–15 per cent of CF patients
(no doubt those who would be properly termed pancreatic sufficient in later
years, with the appropriate genotype) enzyme concentration was normal, but
bicarbonate concentration was very low and the juice was still mucus-like. 
Walker-Smith: It’s interesting how difficult it became to get a faecal fat done.
When I came to the Queen Elizabeth Hospital for Children, Hackney Road,
London, in the 1970s I found faecal fat estimations were no longer being done.
They would have been at the Children’s Hospital in Sydney. I remember I actually
crossed swords with Barbara Clayton about that. She refused to estimate faecal
fats, except in the most exceptional circumstances. I suppose it’s understandable
for laboratory workers not wanting to work with faeces in the labs. Who would
like to make any further comments about diagnosis? Dr Farrell, I cut you off a
little bit earlier when you were talking about diagnosis in the early days.
Farrell: I think we all know the story, but I should like to comment on it just
because of the nature of this Witness Seminar. It was back in August of 1948 that
Paul di Sant’Agnese was taking care of Dorothy Andersen’s patients while she was
here in England on vacation. At the time this large number of patients was being
followed at Babies’ Hospital, Columbia University, New York, during a very
intense heatwave, Paul observed that many of the children admitted for heat
prostration, most of whom died, had ‘cystic fibrosis of the pancreas’ as it was called
at that time. He made the very astute observation that there must be something
about this disease that was leading to the depletion of serum electrolytes. 
He then collaborated with Bob Darling. In April 1952 two children with cystic
fibrosis who were actually teenagers, and two children who were matched
controls, were placed in a constant temperature room, and sweat was collected
for measurement of electrolytes, principally sodium at the time. The difference
was so great between the two with cystic fibrosis and the two others, that, as he
said to me many times, Paul never needed a statistician to analyse the data; and,
in fact he never needed a statistician to analyse any of the data he obtained from
measuring sweat electrolyte concentrations because the difference is so striking.
Paul also pointed out that there were three major dividends of this investment in
research. First, another heatwave came just a few months later, in June 1952, but
this time they were prepared and they brought the patients in to give them
additional salt to prevent death. Second, this improved method of diagnosis with
the sweat test led to the identification of patients that had chronic lung disease,
but pancreatic sufficiency; in other words they had negative duodenal intubation
studies and this was very revealing. Finally and ultimately, Paul’s clinical research
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observations discovered the basic defect in cystic fibrosis, that is the ion channel
or chloride channel defect, which of course is the most significant long-term
implication. I think it’s remarkable that the question arose in Paul’s mind about
electrolytes. What would we do if there wasn’t a sweat test? Would we be better
off without knowing about sweat electrolyte concentrations? It seems incredible
in retrospect that someone would have the interest to determine sweat
electrolytes back in 1952. 
Cuthbert: Perhaps I didn’t quite make it clear why I suggested we might have
been better off without the sweat test, and that was that it led to the domination
of thinking that sodium was the important ion – as you said yourself, the
concentrations of sodium were measured. I just wonder if we would have got to
the chloride channel effect, maybe ten or so years earlier, if the sweat tests hadn’t
existed. That was my point about whether we would now be better off. It’s not a
question we can answer.
Norman: I just wonder whether we should ask Jim Littlewood or John Dodge
to mention the value or not of neonatal screening.145
Littlewood: I think it’s fair to say that people who have been involved with cystic
fibrosis on the ground see no problem about neonatal screening being valuable,
and the various studies have all failed to show a great deal until recently. We will
come to Phil’s in a moment, because the treatment, particularly the Wales–West
Midlands study, which the CF Trust funded, was given for many patients at local
district hospitals, they didn’t have a high standard of treatment. So I think the
general feeling now is that screening with centre treatment is great; if you don’t
have centre treatment, screening is not so valuable. 
But battling away over the years, I am sure you know because you [Archie
Norman] rang me one night asking me why we weren’t screening. I don’t know
whether you remember that, but you asked, ‘Why?’ You had read something in
the newspaper about that. You said, ‘What are you doing at the Trust, you should
be getting this screening going?’ Anyway, we achieved national neonatal CF
screening only after about a six-year battle and after Rosie Barnes had involved
politicians. I think the final little thing that tipped over the national screening
committee to advise the Minister to recommend neonatal screening was the
study from Wisconsin, the very long study, which showed undoubted nutritional
benefit out of, I think, 13 years, wasn’t it really?146
147 See, for example, Simmonds et al. (1998); Littlewood (2000).  
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Most of the clinicians are now absolutely convinced that neonatal screening 
is right. It would be absolutely horrendous to go back to no screening. 
[Walker-Smith: It’s really an argument for special centres again, so this is one of
the great themes, the absolute vital need for care in special centres.] That’s also
being looked at in Scotland where they want to make sure the services match up
to standard before screening is introduced.
That is going to be one of the subjects of a meeting that Kevin Southern over
there is organizing in July, the actual nitty-gritty procedure following a positive
result, who tells them the parents, what do you do? Who looks after the patients?
Who gives the initial advice and talks to the parents? Is it somebody who has seen
numerous cases before, a nurse that’s done it many times before, or is it this team
at a district general hospital, who have seen this once in a blue moon? It’s very,
very difficult, because although saying that the battle has been won about
centres, it has not been won in this country. There are still hospitals who do not
see the need and it was as late as 1990 when a senior academic in this country
said, ‘I don’t know why Jim Littlewood makes all this fuss, any paediatrician
worth his salt (appropriate word) can look after cystic fibrosis’. 
Walker-Smith: You find that across the board in Britain. But what about Kevin
Southern – would he like to make a comment?
Littlewood: We are right behind it, all the clinicians in the country are right
behind it. The Trust circulated them. Unanimous, every paediatrician dealing
with CF was right behind them, very strongly, or strongly believe in it. The
Government were bombarded with these surveys.
Dr Kevin Southern: I completely agree with Jim about the centre care, but for
children who live 100 miles away from a centre, I think the key is that there is
contact with a centre, and I think a local paediatrician can provide a very good
service in our experience, if they work as part of the bigger team. We do
undertake good shared care with many centres throughout the north-west.147
Littlewood: Kevin, can I just say, without wishing to be rude, there is no
scientific evaluation of shared care? I just throw that in to be really cantankerous.
Although I agree with what you said. 
Walker-Smith: You mean as opposed to general practice care, you mean shared
care versus general practice care?
148 Super et al. (1994). See also Elliott (1991); Super (1992).
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Littlewood: There is confusion there – I am glad you raised that point. We are
talking about CF centre–local hospital, similar to obstetrics, with a GP in
hospital. We are not talking about shared care with the GP.
Goodchild: I agree about the benefits to be obtained from newborn screening
having suffered over the years through the Wales–West Midlands screening survey,
which seemed to go on for ever, but which was ultimately successful in achieving
its objective of obtaining newborn CF screening (for Wales initially). However, I
am sitting next to Maurice Super, and I should like to say that one of the benefits
of newborn screening is the opportunity for cascade screening,148 which is one of
the most efficient ways of recognizing the CF carrier, not only within the known
family, but also within the community. I think that’s very important.
Barnes: We are delighted that newborn screening is going to be introduced into
the UK and we are very, very pleased that the Wisconsin study did tip the scales
in terms of the decision being made. We did a huge amount of work over many
years and one thing that we did was a study of the parents of children who were
born between 1994 and 1998 with cystic fibrosis, which we presented to the
then Minister for Health, Yvette Cooper, and I think it was helpful that she was
pregnant at the time, because it focused her mind a bit. 
The one story from that survey which really stuck in our minds, is that of a
mother who had lost her child to cystic fibrosis at the age of 22 months or
thereabouts, only received the diagnosis at the time of death, and was well
advanced in a second pregnancy when this diagnosis was made. As it was so late
in the pregnancy, where she would have automatically terminated the pregnancy,
having had the experience she had had of many months of a very, very sick baby,
she was referred to a CF centre who gave her a lot of reassurance and encouraged
her to proceed with the pregnancy. At the time of our survey, her second baby was
the same age as the first baby when it died, and she made the point that the
disease in the second baby was virtually nonexistent, to all intents and purposes,
compared with the disease in the first baby, who had been under-treated, and we
highlighted that case to emphasize the point. I think there were those kinds of
instances that came through time and time again, which, on top of the statistically
significant evidence from Wisconsin, really did make people take note.
Dodge: I would just like to make a comment on the historical context of both
the Wales–West Midlands screening study and also on centre care. As far as the
149 Report of UK Cystic Fibrosis Survey 1985 to British Paediatric Association, Royal College of Physicians
of London, British Thoracic Society. Unpublished, but main findings summarized in Anon. (1988).
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Wales–West Midlands study was concerned, we alternated and screened all the
babies born in Wales one week and the West Midlands the second week, alternate
weeks, so that half the population was unscreened. We wanted to put the patients
picked up through screening into the regional clinics, and although the CF Trust
eventually funded the study, the original application was to the MRC, and Peter
Weller and I went to the MRC to discuss this project with them, and they said,
‘Oh, that’s no good, because how will you know whether it’s the early diagnosis
through screening or the centre care, if your patients who are screened do better?’
There wasn’t really an answer to that. So that was imposed on us at that stage.
The second thing was the context of that time. Jim will remember that original
report of the British Paediatric Association Working Party, showing that patients
in centres did better than those who were looked after in ones and twos in
general hospital clinics around the country, was initially rejected by the British
Paediatric Association.149 They refused to accept our recommendations until we
toned them down. I had the experience of meeting the BPA council and trying
to talk the report through, and being told by my colleagues, ‘You’re taking all our
interesting patients away from us’. I said ‘Well, this isn’t about paediatricians’ job
satisfaction, this is about where the CF patients will get the best care’. But it was
a pretty hostile atmosphere and we had quite a problem getting it through, and
you, Chairman, were one of the people who helped, because if you remember it
was also discussed at the Royal College of Physicians’ Gastroenterology
Committee, accepted and endorsed, and I should say also by the British Thoracic
Society.150 That’s a historical background to some of these things, and I am sorry
to hear that attitudes have still not changed, at least in some places.
Walker-Smith: I now would like to be very provocative in a general way. I think
paediatric specialists in gastroenterology as well as paediatric specialists in other
organ-based disciplines have lost out by the creation of the new Royal College of
Paediatrics and Child Health. These paediatric specialities sat more easily in the
Royal College of Physicians, where we were plugged in to fellow specialists, in
the case of paediatric gastroenterology into the gastroenterology group. It was
self-evident in the Royal College of Physicians that speciality care was essential.
Within the Paediatric College, sadly in the UK in the year 2002, I think there is
not always such an awareness of the importance of a speciality within paediatrics.
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Super: Just a brief comment, having helped to run peripatetic clinics and to
support what Kevin Southern was saying, and that is because of this really
powerful feeling among paediatricians that they wish to look after their patients
with cystic fibrosis, one has to work with them. I think the big advance has been
that in each district hospital at least they are now selecting one colleague to look
after all the patients with cystic fibrosis and to run the shared care with the 
big clinic.
Littlewood: I still feel that shared care has not been scientifically evaluated
and I am concerned that as the treatment regimes become more clearly
delineated by documents coming out, perhaps from the CF Trust, and the
children being in much better health, there is an increasing reluctance to
evaluate shared care and it’s all right paying lip service to shared care, but
there are problems when you get down to the nitty-gritty, the everyday
management and the lack of CF teams, particularly relating to medical staff
leave and home IV treatment.
Super: It does not need to be lip service. It can be done properly and the CF
Trust can take a lead in making sure that it is done properly. There is a really
powerful feeling among the paediatricians who don’t want to send all their
patients with cystic fibrosis to a big centre, and one has to learn, to find a way
to work with that.
Littlewood: I have been trying that for 20 years, Maurice, running a shared-care
service. Some are excellent, and I know that you have ones in your region that
are excellent, but there are still many who do not believe that they need a CF
centre. I can name three cities in Yorkshire.
Webb: It’s just a curious paradox, as an adult CF physician, we don’t share our
patients with anyone at all. The reason is simplistic actually, it’s because the
paediatricians refer them directly to our centre, there are actually no other
respiratory physicians on the whole who are skilled in CF care. If you turn it
round again, it’s a curious paradox. We have so many patients in our centres now
as adults, we don’t know what to do with the increasing numbers, and so we are
going to lose quality at the expense of quantity. We actually want more centres,
but aren’t quite sure how to achieve it. So the circles change, but we don’t share
our patients with anyone.
Humberstone: Looking at the centres, I am in a situation where my centre is
approximately 100 miles away from me, and my local hospital has said, ‘Really,
looking at the treatment you need, even for everyday care, we are unable to
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provide that’ – so where do I go? I don’t actually want to go into hospital because
of the risk of cross-infection, so I think we have also got to look at something
which hasn’t really been mentioned yet: treatment in the community, in your
own home. This is day-to-day care. We have got to look at community care.
When I speak to the community people, they say, ‘Chest physio is not in the
paperwork’ and they appear uncertain and insecure. It’s not in the paperwork
because – yes – cystics weren’t living long enough at the time the papers were
drawn up. But cystics are, and are going to be, living longer and we have got to
take away the age barrier which would change the view of people treating cystics.
I get very annoyed. Nihilism came out earlier this afternoon about age, and it is
a constant problem.
Somebody asked me at lunch two months ago (and it’s the first time it hit me),
when they asked a younger colleague (who is not CF), ‘What’s your ambition?’
The colleague turned round and said ‘My ambition is…’ She then asked me what
my ambition was, and I thought to myself that I really had no ambition because
I was supposed to have died when I was 16, and then it was 18, and so it has gone
on – even now at the age of 38. If a cystic isn’t strong enough to say, ‘Well, there’s
a first time for everything,’ it is extremely difficult to live through. There is a first
time for everything, good and bad, and I get very annoyed when people fail to
think that how they treat the patient now can affect the patient in the future.
The other day I was at Guy’s, where the ‘doctors of the future’ were present. It
was a training evening where they have to diagnose what disease the patient has.
One student doctor examined me, and was asked what her diagnosis was. In
passing she said, ‘Well, I ruled out cystic fibrosis because she’s too old.’ I sat there
and thought, ‘This is the young doctor of today, and she’s going out on to the
wards and she is going to encounter CF in adults.’ From a patient’s point of view,
there are a number of sensitive issues. We have also got to reach out to the
teaching hospitals and start with the basics, with the doctors who will take care
of you. Somebody asked me once, ‘Well, can’t you tell the doctors?’ If you are in
hospital and that doctor is looking after you for two weeks or more, especially
the young doctors, they do not take advice, and patients really do not want to
upset them. I try to say, ‘I want to help you. I have CF and I have lived with CF
for 38 years, so please listen to me,’ and so on. While we have centres, we have
got to get to local hospitals and to all medics as it’s a constant problem. We have
to get out to the local hospitals, to GPs and care staff. What do I do?
I have recently had two years’ bad health because I have had no support for my
physio needs. I think that if they had kept the physio going I would be OK.
Cystic Fibrosis
72
Now, I know that I am referring to my own experience, but there must be other
cystic fibrosis patients out there too in a similar position. Now, they say parents
tend to do the physio. My father is aged 70 and still he says, ‘Tracy, do you need
physio?’ He lost an elder daughter to CF, he has had two hip replacements,
arthritis of the knees, four discs worn in his spine, and this is the person offering
to do my physio! We have got to get out there and look at the community. CFs
are living longer, so let’s get out there and give them care. I do not want my
parents involved in my care. I can (and do) live on my own but I need support
from community physios when I need it. I would like my parents to go to their
graves knowing that I am cared for.
When I am seriously ill and I think there’s a problem beyond the knowledge of
the community people, then I go to my centre. But, to be honest, to put yourself
into local hospitals is pointless, life-threatening and very frustrating. 
So there are a number of things to be done. Change the view of people – cystics
are living longer. When people give averages and facts about the treatment of the
condition, it’s a new condition and the facts are fairly new when it comes down
to papers and statements, so it is better saying, ‘We have only been collecting the
information over so many years, so we can only tell you this is based on recent
research.’ It is such a dead-end job for carers and patients when, at 38, that’s it.
I know through reading international newsletters that people do live longer. I can
tell you all now that medical care is not always as good for older patients. In fact,
you tend to feel that doctors are thinking, ‘Well, she’s only going to live 
to whatever age, so what’s the point?’ I’ve noted quite a few things from 
others’ contributions.
Walker-Smith: I think you have made an eloquent testimony about community
care being particularly important. Then, of course, I think there is a
responsibility of specialists in a centre to achieve the community care that is right
for you. Also, the other observation of why young doctors should be encouraged
to listen to patients with experience. That’s rather a criticism of young doctors if
they don’t listen to the patients. We must train young doctors to be more
receptive perhaps.
Littlewood: I have enjoyed very much hearing all these comments, and Tracy
Humberstone’s. I think, quite honestly, it is a hopeless task to train everybody
who is going to deal with cystic fibrosis throughout any small hospital in any
part of this country. Every difficult serious disease now is dealt with, should be
dealt with, by teams of experts who see hundreds of patients, and what I have
heard today has strengthened my view that CF centre care, really rigid, not
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perhaps all attendances, but not just lip service, should be available for everybody
in this country. Amateurism should be finished now in managing these diseases. 
Walker-Smith: Now we have two last comments before we conclude today and
you are first, David.
Stableforth: I would like to speak up strongly for shared-care medicine for cystic
fibrosis in adult patients. I have heard a lot of opposition to it here today. I work
in a big region, 40–50 miles in diameter. You cannot expect patients to travel
that sort of distance on a daily basis, for their day-to-day treatment needs.
Exclusive care by major centres is absolutely fine, but in the West Midlands we
have a small network of people who are experts but who look after small
numbers of patients. Some physicians in the West Midlands find that shared care
between paediatric and adult centres works well where there are interested and
enthusiastic specialists.
I think that we should encourage the development of shared-care schemes,
because there are going to be more cystic fibrosis patients and more people in the
dilemma of the young lady patient who spoke previously. I think the way
forward is going to be to develop this. 
Raeburn: Unlike Jim, I didn’t think that what Tracy said was making the case for
centre care. I think what she was doing was making a case for professionals
listening to the patient, and developing a programme of care with them,
wherever they live, so that the best of the local resources and the best of the
centres can be applied to that individual’s healthcare.
Southern: Obviously centres that specialize in cystic fibrosis care have got to lead
the way. I have really enjoyed today, like Jim, and what’s come through to me has
been the enormous enthusiasm and warmth that you all have. I was born in
1964, so hardly qualify to be here. Rather than focusing on the specialist centre
versus shared care, which I believe can be done well and properly, with
enthusiasm, I would like to finish on the point that maybe something that we
have learnt over the last 50 years is that we need to listen to the patients more. I
get the slight impression from what some people have said that it’s been an
experimental 50 years, and that maybe at times the patients haven’t been listened
to. I hope that patients have greater input into the partnership that we are
hoping to forge over the next 50 years.
Duncan-Skingle: I would first like to reassure Tracy that there are many patients
in their 40s, 50s, 60s, and our oldest is 72, so hopefully she will have a long and
productive life. I think all of us have an uphill struggle as healthcare
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professionals, trying to fulfil what patients perceive as their needs and rights. We
must listen to patients, that’s the way we have always learned, and is the reason
why a lot of things have developed in the way they have today. I think
community care is an excellent idea, and that home care from specialist centres
could be developed further. In the future, nurse-led clinics for the patients could
be the way forward, especially for the less seriously affected patients that are
reaching adult life. It is a challenge for us all, in the future.
Madge: I was just going to remind people about the home-care service that’s
currently spreading throughout the country from the top of Scotland, right
down into the south-west, where specialist centres are providing a home-care
service for the day-to-day needs of their patients, and encouraging community
nurses who are not necessarily CF experts, but they are getting training to look
after their CF patients for their home care, rather than having to travel to centres
quite so regularly.
Humberstone: The one point I was trying to make earlier – yes, I do agree with
the need for centres but there has to be a package put together – knowledge,
education, coming through from patient to GP to local hospitals to the CF
centres, and there has to be communication between all four. There has to be
something set up so that you have the transition from birth onwards, because the
GP is not educated in CF so, straightaway, the person who is your closest and
first point of call does not know. I am speaking from my experience and from
what I have heard over the years.
So yes, I agree that the centres should be there but I have to say that from a
patient’s point of view, (and I have always kept myself well), I have isolated
myself from centres; I absolutely hate going to the centre and will only go there
if I have to. It’s nearly always me phoning up to say, ‘I need IVs’, but I will not
go there for routine checks for fear of cross-infection. And I have a good centre
that isolates cases. 
Until the knowledge is greater than my centre, I would not go to the Brompton
because there are too many cystic fibrosis patients there. So, have smaller centres
that are experienced and more local to people in my opinion, and I think that is
the way forward, working with the community team to keep you in your own
home and also to break that barrier, because having had a partner who turned
round and said, ‘Tracy, I am sorry, I am forever seeing you as a sick person’. Why?
Because he did my physiotherapy every night – that has to be considered too.
The way forward is also looking at adult problems to prepare for the younger
generation. If you do not lift the age barrier, the problems will not go away.
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Walker-Smith: I am sure that one fundamental problem you [Tracy] raise is the
problem of communication within the National Health Service. There is often
inadequate communication between the consultants in the hospital centres and
the periphery (i.e. the community and GPs).
Humberstone: The communications problem has been there for years and it has
not improved, except in the centres. One thing I would like to say is ‘thank you’
to all those dedicated people who have worked on CF over the years and
particularly through the years when CFs were not surviving long. So I thank
everyone in this room that has worked on CF and ask them please to continue. 
Walker-Smith: We are all extraordinarily grateful to all of you witnesses here
today, who have made such a memorable contribution. The only thing I can say
at the end: so much has been done, yet there’s so much to be done. Thank you
all very much.
Tansey: On behalf of the History of Twentieth Century Medicine Group, 
I would like to thank you all very much for participating in this afternoon’s
Witness Seminar, and also to thank John for his excellent chairing of 
this meeting.
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Ms Su Madge 
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Dr Margaret Mearns 
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later worked at the Queen Elizabeth
Hospital in Hackney where
Winifred Young ran a clinic for
children with cystic fibrosis. On her
retirement Dr Mearns was asked to
take over the clinic. She retired
from medical practice in 1989.
Sir George Newman 
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(1870–1948) was Chief Medical
Officer to the Ministry of Health
from 1919 to 1935 and to the
Board of Education from 1907 to
1935. See Brown (1955).
Dr Archie Norman 
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Physician to the Hospital for Sick
Children, Great Ormond Street,
London, from 1950, and
Paediatrician to Queen Charlotte’s
Maternity Hospital, London, from
1952 until his retirement in 1977.
From 1976 to 1984 he was
Chairman of the Medical Advisory
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Research Trust.
Dr Wilfred Payne 
FRCP (1894–1978) was a research
biochemist at Queen Charlotte’s
Hospital, London, from 1959 to
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London, from 1926 to 1959. 
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counting, and did pioneering 
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metabolism. He received the
Dawson Williams Prize in 1959 
and the James Spence Medal in
1971. See Cathie (1984).
Professor Paul Quinton 
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at the University of California
Riverside, USA. He also holds the
Nancy MacCracken Chair in
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the Department of Pediatrics,
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Professor Sandy Raeburn 
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currently Professor of Genetics in
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Professor of Clinical Genetics at
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the Queen and President of the
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Professor Margot Shiner 
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in the 1950s and in 1956 invented
a technique of small bowel biopsy
that could be used to diagnose
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Professor Harry Shwachman 
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of the Scientific/Medical Advisory
Council of the International Cystic
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Dr Kevin Southern 
FRCPCH (b. 1964) has been Senior
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Cystic Fibrosis Centre at
Birmingham Heartlands Hospital
since 1977.
Sir John Sulston 
Kt FRS (b. 1942) was a staff
scientist at the MRC Laboratory of
Molecular Biology, Cambridge,
from 1969 to 1992. From 1992 to
2000 he was Director of the Sanger
Centre, Hinxton, Cambridge, where
he oversaw the Human Genome
Project. He shared the 2002 
Nobel Prize for Physiology or
Medicine with Sydney Brenner 
and Robert Horvitz. 
Dr Maurice Super 
FRCP FRCPCH (b. 1936) is
Honorary Consultant Paediatric
Geneticist at the Royal Manchester
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Children’s Hospital. He was the
Head of the Department of Clinical
Genetics and Honorary Lecturer in
the Department of Medicine at the
University of Manchester
(1979–2001), and worked as a
consultant paediatrician in South
West Africa (now Namibia)
(1967–78), where he researched his
MD thesis, ‘Cystic fibrosis in South
West Africa’ (1978). 
Professor Lap-Chi Tsui 
FRSC FRS (b. 1950) has been
Director of the Centre for Applied
Human Genomics, Hospital for
Sick Children, Toronto, Canada,
since 1998. He has been Geneticist-
in-Chief and Senior Research
Scientist at the Centre since 1983.
Mr Ron Tucker 
OBE was appointed as the Cystic
Fibrosis Trust’s first Executive
Director and retired in 1983 after
18 years’ service. In 1990 he became
Vice President of the Trust.
Dr Bernard Valman 
FRSM FRCP FRCPCH (b. 1934)
was consultant paediatrician at
Northwick Park Hospital and the
Clinical Research Centre, Harrow,
(1972–99). He was Secretary to the
Royal College of Physicians Paediatric
Committee from 1981 to 1991.
Professor Selman Waksman  
(1888–1973) became Professor of
Microbiology at Rutgers University
in 1930 and was awarded the Nobel
Prize in Physiology or Medicine in
1952 for his discovery of
streptomycin. His 1916 MSc thesis
focused heavily on actinomycetes.
Professor John Walker-Smith 
FRCP FRACP FRCPCH (b. 1936)
was appointed Consultant/Senior
Lecturer in Child Health at St
Bartholomew’s and Queen Elizabeth
Hospital for Children in 1973, and
became Professor of Paediatric
Gastroenterology in 1985. He
transferred to the Royal Free
Hospital, London, in 1995 and
spent a sabbatical in history of
medicine at the Wellcome Institute
for the History of Medicine in
1993. He retired in October 2000,
and has been Emeritus Professor of
Paediatric Gastroenterology and
Research Associate in the History of
Medicine since October 2000, and
a member of the History of
Twentieth Century Medicine Group
since 1993.
Professor Warren Warwick 
(b. 1928) is Annalisa Marzotto
Professor of Cystic Fibrosis in the
Department of Pediatrics, University
of Minnesota, USA. He graduated
from the University of Minnesota
Medical School in 1954, and was
Associate Professor of Pediatrics at
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the University of Minnesota from
1966 to 1978. Since 1962 he has
been Director of the Cystic Fibrosis
Care, Research and Teaching Center
at the University of Minnesota
Medical Center.
Professor Kevin Webb 
(b. 1946) is Clinical Director of the
Manchester Adult Cystic Fibrosis
Centre, which currently cares for
around 250 patients. He founded the
Centre in 1982 with Mrs Mary Dodd.
Dr Peter Weller 
FRCP FRCPCH is Consultant
Paediatrician in Respiratory
Medicine at Birmingham Children’s
Hospital. He qualified from St
Thomas’ Medical School, London,
in 1969.
Professor John Widdicombe 
FRCP (b. 1925) was Foundation
Professor and Chairman of
Physiology, at St George’s Hospital
Medical School, London, from
1972 to 1992. He is now ‘retired’
and an Emeritus Professor of
Physiology in the University 
of London.
Dr Jonathan Widdicombe
(b. 1949) worked in the
Cardiovascular Research Institute,
San Francisco (1975–95), and is
now at the University of California,
Davis, Sacramento.
Professor Robert (Bob)
Williamson 
FRCP FRCPath FRS (b. 1938) 
was Professor of Biochemistry at 
St Mary’s Hospital Medical School,
London, from 1976 to 1995. He
has been Research Professor of
Medical Genetics, University of
Melbourne School of Medicine, 
and Director, Murdoch Children’s
Research Institute, Royal Children’s
Hospital, Melbourne, since 1995.  
Dr Winifred Young 
FRCP DCH (1909–69) was a
research clinician at the Queen
Elizabeth Hospital for Children,
London, from 1948 to 1969. She
started a special clinic for children
with cystic fibrosis at the hospital in
1950. She established the
importance of prolonged intensive
therapy of lung infections in
affected babies. See Wilmers (1982).
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Actinomycetes
A group of bacteria that grow slowly
as branched filaments. Together with
the mycobacteria they make up the
Actinomycetales; Streptomycetaceae
are the source of most antibiotics.
Aminoglycosides
A group of antibiotics used to
combat bacterial infections, especially
infection from Pseudomonas sp. and
Staphylococcus sp. Examples include
gentamicin and tobamycin.
Antibiotic
A medication that is used to treat
infections caused by bacteria. They
have no effect on illnesses caused 
by viruses.
Antibiotic resistance 
When bacteria can no longer be
killed by a particular antibiotic, for
example, MRSA. 
Aureomycin (chlortetracycline
hydrochloride: Lederle)
A yellow crystalline antibiotic used
to treat certain bacterial and
rickettsial diseases.
Bacillus pyocyaneus
An earlier name for Pseudomonas
aeruginosa.
Biopesticide
A pesticide in which the active
ingredient is a virus, fungus, or
bacteria, or a natural product derived
from a plant source. Its mechanism
of action is based on biological
effects and not on chemical poisons.
Bronchiectasis
The irreversible, abnormal structural
dilatation of one or more bronchi,
accompanied by chronic infection.
Bunyan bag
A plastic bag used to enclose
severely burned limbs.
Burkholderia cepacia (Pseudomonas
cepacia)
A species of Burkholderia. It is
considered to be a human pathogen
with serious consequences for
people with cystic fibrosis. It can
cause rapid decline in lung
function, resulting in severe lung
disease that may lead to death. 
Chlortetracycline hydrochloride
See Aureomycin.
Carbenicillin
A semisynthetic penicillin that is
acid labile and the first penicillin to
be active against Pseudomonas.
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CFTR 
See cystic fibrosis transmembrane
conductance regulator.
Chloramphenicol
An antibiotic produced
synthetically and from cultures of
Streptomyces venezuelae. It is used as
an antibacterial agent.
Cholecystokinin (pancreozymin)
A hormone secreted by the
duodenal and upper jejunal mucosa.
It stimulates the gall bladder to
contract, and release pancreatic
enzymes and bile. 
Cotazym
An older preparation of pancreatin.
Crohn’s disease
A chronic inflammatory bowel
disease involving the small intestine,
the colon or both, and characterized
pathologically by transmural
inflammation, deep linear ulceration
and often granulomas. 
Crossed immunoelectrophoresis
A method of demonstrating
antibodies in the blood.
Cystic fibrosis (Mucoviscidosis)
An inherited disorder that causes
widespread dysfunction of the
exocrine glands, resulting in chronic
lung disease, abnormally high levels
of electrolytes (e.g. sodium,
potassium, chloride) in sweat, and
deficiency of pancreatic enzymes
needed for digestion. 
Cystic fibrosis transmembrane
conductance regulator (CFTR)
The protein product of the cystic
fibrosis gene. Functionally the gene
encodes a protein that is responsible
for regulating the opening and closing
of chloride channels. This protein is
the most important apical membrane
transporter for chloride.
Delta F508 
One of the abnormal alleles, the
most common, within the cystic
fibrosis gene; a deletion of
phenylalanine (F) at amino-acid
position 508 of CFTR.
Electrolyte
A substance that yields ions in
solution so that its solutions
conduct electricity.
Epithelium
The cellular covering of the skin
and mucous membranes.
Fibrosis
The deposition of collagen, usually
in the form of a scar, surrounding
parenchymal cells. 
G551D 
One of the abnormal alleles within
the cystic fibrosis gene.
Genotype
The total genetic information in 
a somatic cell, or the total genetic
information in a germ cell or
organism. 
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Gentamicin
A broad-spectrum antibiotic that
inhibits bacterial protein synthesis
and is active against many Gram-
negative and Gram-positive bacteria,
particularly Pseudomonas aeruginosa. 
Glycoprotein
Any type of protein that possesses a
sugar within the molecule.
Intralipid
An intravenous fat emulsion used 
to treat people who are unable to 
eat properly.
Intussusception
The telescoping of one segment of
the intestine within a neighbouring
segment, most commonly the ileum
into the colon.
Jaundice
A phenotypical expression caused 
by the presence of bilirubin in 
body fluids, which results in the
yellowing of eyes and skin. This 
can be a result of excess destruction
of red blood cells or of liver failure.
KM19 
A marker within part of the 
cystic fibrosis gene (exon 6).
Meconium ileus
The intestinal obstructive variant 
of cystic fibrosis or mucoviscidosis.
Approximately 15–20 per cent of
infants with cystic fibrosis also
present with intestinal obstruction
related to meconium ileus.
Messenger RNA (mRNA)
The RNA that carries the
information encoded in a DNA
sequence to the site of protein
biosynthesis, where it specifies the
order of amino-acid residues.
Methicillin-resistant Staphylococcus
aureus (MRSA)
A subgroup of Staphylococcus
aureus that cannot be killed by
many frequently-used antibiotics,
including methicillin.
Mucin
Any mucoglycoprotein secreted by
cells which raises the viscosity of the
medium around them.
Mucolytic
An agent that dissolves or destroys
mucin.
Mucoviscidosis 
A term for cystic fibrosis commonly
used in continental Europe.
Nebulizer
A device for converting liquid into a
mist or cloud, used primarily for
direct inhalation. 
Pancrease
An early acid-resistant pancreatic
enzyme preparation. See page 26.
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Pancreatin
A product derived from hog or ox
pancreas and containing enzymes such
as amylase, protease and lipase, which
have the same actions as pancreatic
juice. When administered to patients
with pancreatic insufficiency it
improves their ability to metabolize
starches, protein and fats. 
Pancreozymin
See cholecystokinin.
Penicillin
A group of ß-lactam antibiotics.
The naturally occurring penicillins
(penicillin G) are active chiefly on
Gram-positive organisms. 
Phagocytosis
The ingestion of materials from the
outside of the cell into its exterior.
Polysaccharide
A complex carbohydrate consisting
of many smaller monosaccharide
components.
Pseudomonas aeruginosa
A Gram-negative organism
characteristic of, but not exclusive
to, cystic fibrosis lung infections.
Pseudomonas cepacia
An earlier name for Burkholderia
cepacia.
Recombination
Any process occurring during
reproduction which results in an
offspring with a combination of two
or more genes that is distinct from
the arrangement of those genes in
either parent.
Secretagogue
An agent that stimulates a secretory
action, especially for example the
exocrine glands.
Secretin
A type of hormone that promotes
the secretion of bile from the liver.
Staphylococcus aureus
A type of bacteria commonly
found in the environment and
sometimes found in the nose and on
the skin of healthy people. It can
cause several types of infections,
including skin and wound infections,
and less commonly pneumonia.
Steatorrhea
The presence of excess fat in the
stool. It is generally an indication of
malabsorption.
Stenotrophomonas (Pseudomonas)
maltophilia
An aerobic Gram-negative bacillus
that is an infrequent pathogen in
humans and is found in a variety of
aquatic environments. It is
multidrug resistant and occasionally
causes bacteraemic and organ-
specific infections in humans.
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Sweat test
This test determines the amount of
chloride in the sweat. A chemical,
known to cause sweating is applied
to a small area on an arm or leg. An
electrode is then attached and a
weak electrical current applied to
the area to stimulate sweating. The
sweat is then collected and analysed.
Children and adults with CF have
an increased amount of sodium and
chloride (salt) in their sweat. In
general, sweat chloride
concentrations less than 40 mmol/L
are normal (does not have CF);
values between 40 to 60 mmol/L
are borderline, and sweat chloride
concentrations greater than 60
mmol/L are consistent with the
diagnosis of CF. 
Tetracycline (Terramycin,
oxytetracycline: Pfizer)
A broad-spectrum antibiotic.
Terramycin 
A trade name for tetracycline, 
see above.
Trypsin
A pancreatic proteinase that
hydrolyses polypeptides on the 
C-terminal side of arginine and
lysine residues. 
Xerophthalmia
Abnormal and severe dryness of the
surface of the cornea and
conjunctivae as may occur in
vitamin A deficiency or some
autoimmune syndromes.
XVC2 (gene locus)
A sequence of DNA very close to
the cystic fibrosis gene.
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Actinomyces antibioticus, 31
actinomycetes, 31, 101
actinomycin A, 31
adolescent medicine, 27, 33
adults, 11, 38, 74
cohort effect, 22
independence, 38
patient’s viewpoint, 71–3, 75
services, 16–17, 26, 35, 71
specialist centres, 17, 28, 34, 71–2, 
74–5
transition from paediatric care, 27, 
28–30, 32–4, 37–8
advocacy project, 38–9
aerosol therapy, 9, 47, 49
age
barriers, 37, 72, 73, 75
pathogenic bacteria and, 50, 57
survival, 11, 14, 15, 74
see also adults
airway
mucus see mucus
obstruction, mist-tent related, 24
airway epithelium
cell culture, 45
water and electrolyte transport, 44–7
alginate, Pseudomonas, 51, 52–3
American Journal of Respiratory Disease
and Critical Care Medicine, 64
aminoglycosides, 16, 24, 58, 101
antibiotics, 4, 49–51, 101
advances in treatment, 15, 16
adverse effects, 24
discovery, 31, 50
early use, 8–9
IV treatment see intravenous treatment
nebulized, 16
prophylactic, 5, 24
resistance, 53, 54–5, 101
see also chloramphenicol, gentamicin,
aminoglycoside
aureomycin, 5, 101
see also antibiotics
Australia, 52, 58, 62
survival statistics, 15, 18, 19–21
see also Sydney, Victoria
Babies’ Hospital, Columbia University,
New York, 3, 4, 7–8, 66
Bacillus pyocyaneus, 49, 57, 101
see also Pseudomonas aeruginosa
Bayer, Leverkeusen, Germany,  51
Belfast, 21, 36
bicarbonate, 46, 65–6
biofilms, 52
biopesticides, 56–7, 58, 101
biopsy, small intestinal, 13–14
Birmingham, 6, 28–9, 64–5
Birmingham Heartlands (formerly East
Birmingham) Hospital, Birmingham,
31–2
bone fragility, 24
Boston Children’s Hospital, Boston,
MA, 30
BPA see British Paediatric Association
Brighton, 55, 63
British Paediatric Association (BPA),
London
centre-based care, 15, 22
Cystic Fibrosis Survey, 19–20
Working Party on Cystic Fibrosis, 
15, 28, 70
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Index: Subject
British Thoracic Society, London, 15,
19–20, 28, 70
Brompton Hospital see Royal
Brompton Hospital
bronchiectasis, 101
Bunyan bag, 10, 101
Burkholderia cepacia (formerly
Pseudomonas cepacia), 19, 56–7, 101
biopesticides, 56–7, 58, 101
cross-infection, 25, 31–2, 35
emergence as pathogen, 53, 54–5
California University, Davis,
Sacramento, 43
camps, cystic fibrosis, 25, 34–5, 51
Canada
CF camps, 31, 35
CF gene mutations, 61
survival statistics, 18, 19–21
carbenicillin, 16, 101
Cardiff, 21, 35, 36
carrier detection, 60, 69
Carshalton, Queen Mary’s Hospital, 5, 39
centres (clinics), cystic fibrosis, 9,
15–17, 31–4, 73–4
access problems, 39, 71–2, 74
adults, 17, 28, 34, 71–2, 74–5
benefits, 17, 19, 20, 22, 26, 68, 69–70
CF Trust funding, 16, 37–8, 41, 42
costs, 21
disadvantages, 212
early, 6, 11, 12–13, 14, 21
impetus for setting up, 15–16, 21, 35
numbers of patients required, 28
patient’s viewpoint, 73, 75
relationships between patients, 31–2
shared care with local hospitals, 
68–9, 71, 74
transition from paediatric to adult 
care, 27, 28–30, 32–4
Wales–West Midlands study, 67–8, 
69–70
CF see cystic fibrosis
CFRT see Cystic Fibrosis Trust
CFTR see cystic fibrosis transmembrane
conductance regulator
CFTR gene see gene, cystic fibrosis
chest infections see pulmonary
infections
chest medicine clinics, 33, 71
chest tapping, 5
Children’s Hospital, Philadelphia, 7
chloramphenicol, 13, 102
chloride
airway epithelial transport, 44–7
in sweat, 47–8, 65, 105
chlortetracycline hydrochloride
(aureomycin), 5, 101
cholecystokinin (pancreozymin), 65, 102
cholera, 49
chromosome 7, human, 59
chromosome 19, human, 62–3
chronic lung disease
antibiotic efficacy, 9, 58
early reports, 3, 7
genotype correlations, 63
microbiology, 48–59
see also pulmonary infections
chymotrypsin, 65
ciprofloxacin, 50–1
coeliac disease, 27–8
coeliac syndrome, 3
colistin, 16
colonic strictures, 24–5
community care, 72, 73, 75
conferences, international, 19, 59, 63
Cotazym, 25, 102
Creon, 30
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Crohn’s disease, 27, 40, 102
crossed immunoelectrophoresis, 14, 58,
102
cross-infection
CF camps, 25, 31, 34–5, 51
CF centres, 31–2, 75
emerging pathogens, 53, 54
via mist-tents, 24
CS7 gene, 60
cystic fibrosis (CF), defined, 102
Cystic Fibrosis (CF) Foundation, USA, 63
‘cystic fibrosis of the pancreas,’ 7, 11,
50, 66
Cystic Fibrosis Survey, UK, 15, 19–20,
28, 36
cystic fibrosis transmembrane
conductance regulator (CFTR; CF 
gene product), 102
distribution of expression, 48
function, 46, 47, 48
molecular model, 61
Cystic Fibrosis Trust (formerly Cystic
Fibrosis Research Trust; CFRT), 
35–43, 63–4, 71
CF Survey, 19–20, 36
clinical care funding, 16, 37–8, 40–2
formation, 11, 39
promotion of CF centres, 21, 35, 41
Research and Medical Advisory 
Committee (RAMAC), 35–7, 
39–40, 63
research funding, 35–6, 38, 39–40, 
41–2, 43, 63, 67, 70
sources of money, 37, 63
transition to adult care, 29
databases, 13, 36, 38
deafness, 24
delta F508 mutation, 60, 102
geographical distribution, 61
phenotypes, 61–2
Denmark, 14, 17, 33, 52, 59
diagnosis, 64–7
1945–55, 5, 8, 9
mistaken, 14
small intestinal biopsy, 13–4
dietary management, 5, 16, 17, 22, 23
see also nutrition
dieticians, 6, 16, 21, 25–6
doctors, 26
psychological aspects, 34
relationships with patients, 32
young, 72, 73
drug discovery, 31
Duchenne muscular dystrophy gene, 42
duodenal intubation, 5, 7, 8, 13, 65–6
East Birmingham (now Birmingham
Heartlands) Hospital, 31–2
Edinburgh, 21, 27, 53, 54
electrolyte, 102
defect, sweat glands, 7, 9, 47–8, 66–7
transport, airway epithelium, 44–7
EMLA cream, 17
ENaC (epithelial sodium channels), 47
enteral feeding, 16
Environmental Protection Agency,
USA, 56–7
enzymes, pancreatic see pancreatic
enzymes
epithelial sodium channels (ENaC), 47
epithelium, 102
airway see airway epithelium
Escherichia coli, 54, 64
European Cystic Fibrosis Conference, 63
eye changes, 13
faecal fat, 65, 66
familial pancreatic cystic fibromatosis
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with bronchiectasis, 3
family see parents/family
family doctors see general practitioners
fat, 24, 25
dietary intake, 25–6
dietary restriction, 5, 17, 22, 25, 26
faecal, 65, 66
supplements (including Intralipid), 
14, 22, 23, 25–6
Fibrocystic Disease of the Pancreas
(Bodian), 6
fibrosis, 102
flatus, 5
G542X mutation, 62
G551D mutation, 62, 102
gastroenterology, paediatric, 70–1
gene, cystic fibrosis (CFTR)
discovery, 59–64
mutations, 61–2
protein product see cystic fibrosis 
transmembrane conductance
regulator
research, 36, 42, 63
gene expression studies, 60, 61
gene jumping, 60
gene therapy, 47
genome size, bacterial pathogens, 54–5
genomic fingerprinting, bacterial
pathogens, 53, 54, 56
genotype, 102
genotype–phenotype correlations, 61–3
gentamicin, 16, 24, 58, 103
glycoproteins, 45, 103
GOS see Great Ormond Street
GPs (general practitioners), 21–2,
68–9, 75
Great Ormond Street (GOS) Hospital,
London, 4, 5–6, 11, 13, 15–16, 20, 30
guidelines, clinical, 38
guinea-pig, research, 47
Haemophilus, 49, 50, 57
Haemophilus influenzae, 49, 50, 54, 57,
64
heart–lung transplantation, 17–18, 36
heatwaves, 10, 66
histology, 6
home
care for adults, 72, 73, 75
GP-based care, 21–2
IV treatment, 17, 22, 71
Human Genome Conference, 1984, 59
hydropathy plot, 61
iatrogenic problems, 23–5
immune response, 57, 58
immunoelectrophoresis, crossed, 14,
58, 102
infertility, male, 6, 13, 31
interdisciplinary bridging, 54–5, 56
International Burkholderia cepacia
Working Group, 56
International Cystic Fibrosis Congress,
1988, 19
Intralipid, 14, 23, 25, 103
intravenous (IV) treatment, 17, 19, 22,
32–3, 71
intussusception, 14, 103
investigations, confirmatory, 64–7
iodine/iodides, 12, 52
ion transport, airway epithelium, 44–7
IV treatment see intravenous treatment
jaundice, 103
neonatal, 14
jejunal biopsy, 13–14
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Kinderspital, Zurich, 3
KM19 gene locus, 60, 103
Koch’s postulates, 58
Lancet, 16, 56
lay people, CF Trust research
committee, 36–7
Leeds, 16, 25–6, 33–4
leukaemia, acute lymphocytic, 8
listening to patients, 72, 73, 74, 75
local anaesthetic (EMLA) cream, 17
lung disease, chronic see chronic lung
disease
male infertility, 6, 13, 31
malnutrition, 22
Manchester, 12, 26, 54, 59, 61
meconium ileus, 103
as cause of death, 20
equivalent, 13
genotype correlations, 62–3
Medical Research Council (MRC), 40, 
41, 70
Travelling Research Fellow, 52
messenger RNA (mRNA), 103
Met oncogene, 59
methicillin-resistant Staphylococcus
aureus (MRSA), 53, 103
microbiology, 21, 31, 38, 48–59
microspheres, acid-resistant, 17, 24–5, 
26, 30 
see also pancreatic enzymes
misdiagnosis, 14
mist tents, 11–13, 14, 24
mortality
early sweat tests, 10, 24
first year of life, 20
see also survival
mouse models, 47, 62
MRC see Medical Research Council
MRSA (methicillin-resistant
Staphylococcus aureus), 53, 103
mucin, 49, 103
mucolytic, 12, 103
mucoviscidosis, 43, 103
see also cystic fibrosis
mucus (airway)
flow rate measurements, 44
hydration therapy, 12
research studies, 43–7
secretion, 45, 48
viscosity, 46–7
vs sweat, 48
multidisciplinary care, 6, 16, 21, 26
multidrug resistance, 55
Namibia, South West Africa, 23
National Health Service (NHS), 5
Cystic Fibrosis Trust support, 35, 40–2
communication within, 75, 76
National Institutes of Health, 7, 63
nebulized antibiotics, 16
nebulizers, 12, 103
neonatal jaundice, 14
neonatal screening, 14, 67–8, 69
nephrotoxicity, aminoglycoside, 24
New York, 3, 4, 7–8, 66
New York Postgraduate Hospital, 7
New Zealand, 14
NHS see National Health Service
nihilism, 22, 23, 37, 72
nurses, 21
community, 75
psychological aspects, 34
relationships with patients, 32
specialist cystic fibrosis, 28, 33
nutrition, 16, 17, 22, 23, 25
see also dietary management
Oxford, 59
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paediatricians
general vs specialist, 9, 22, 35, 39, 
68, 71
handover to adult physicians, 27, 
28–30, 32–4
paediatrics, 4, 27–8, 70–1
Pancrease, 17, 22, 26, 30, 103
pancreatic enzymes
acid-resistant microspheres, 17, 24–5,
26, 30
in duodenal juices see duodenal
intubation
high dose, 24, 25
in stool specimens, 5
tablets/powder, 5
see also Pancrease; trypsin
pancreatic function tests, 5, 7, 8, 13, 
65–6
pancreatic sufficiency
diagnosis, 65–7
genotype correlations, 61–3
pancreatin, 6, 104
pancreatitis, 14
pancreozymin (cholecystokinin), 65, 102
paraoxonase, 59
parenteral therapy, 9
see also intravenous treatment
parents/family
adults with CF, 38, 73
CF Trust research committee, 37
impact of nihilism, 22, 23
at initial diagnosis, 68
transition to adult care and, 29–30
pathologists (morbid anatomists), 5–6, 7
patients
CF Trust research committee, 36–7
compliance with low-fat diet, 26
impact of nihilism, 22, 23, 72
listening to, 72, 73, 74, 75
relationships between, 31–2
relationships with staff, 32
viewpoint, 37, 71–3, 75, 76
penicillin, 5, 58, 104
early use, 8–9, 49
resistance, 54–5
pH, mucus, 47
phagocytosis, 104
‘frustrated,’ 52
pharmaceutical companies, 21, 31, 41
Philadelphia, 4, 7, 20
physiotherapists, 6, 16, 21, 26
physiotherapy
adults with CF, 38, 72–3, 75
introduction, 5
pilocarpine iontophoresis, 10–11, 64–5
pJ3.11, DNA probe, 59–60
pneumonia see pulmonary infections
polyps, 13
polysaccharide, 104
postural drainage, 5
prenatal diagnosis, 60
prognosis see survival
protein, dietary intake, 5
Pseudomonas aeruginosa (formerly
Bacillus pyocyaneus), 23, 49, 64, 104
antibiotic resistance, 55
antibiotic therapy, 9, 51, 58
cross-infection, 24, 25
immune response, 14, 58
mucoid alginate-producing, 51, 52–3,
59
pathogenicity, 57, 58, 59
prophylactic antibiotics and, 24
rough, smooth and mucoid types, 59
Pseudomonas cepacia see Burkholderia
cepacia
Pseudomonas maltophilia see
Stenotrophomonas maltophilia
psychosocial aspects, 22, 24, 25, 34
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pulmonary infections
as cause of death, 8
prophylaxis, 5, 24
treatment, 5
see also chronic lung disease; 
microbiology
Queen Elizabeth Hospital for Children,
Hackney, London, 6, 11, 13, 15–16, 
27–8, 66
Queen Mary’s Hospital, Carshalton, 5
RAMAC see under Cystic Fibrosis Trust
recombination, 104
research
basic (laboratory and scientific), 
35–6, 39, 41, 43–64
CF Trust funding, 35–6, 38, 39–40, 
41–2, 43, 63
early, 5–6
Research and Medical Advisory
Committee see under Cystic 
Fibrosis Trust
reverse genetics, 59
Riordan domain, 61
Rome University Medical School, 7
Royal Alexandra Hospital for Children,
Sydney, Australia, 3, 13–14, 66
Royal Brompton Hospital, London, 13,
22, 28, 30, 33
CF clinic, 11, 16–17, 75
CF Trust grants, 36
Royal College of Paediatrics and Child
Health, London, 70–1
Royal College of Physicians, London,
15, 28, 70
Royal Society of Medicine (RSM), 4
RSM (Royal Society of Medicine), 4
Science, 60
SCOPE (formerly the Spastics
Association), 39
Scotland, 21, 27, 29, 34, 61, 68, 75
screening
cascade, 69
neonatal, 14, 67–8, 69
seaweed, 12, 52
secretagogue, 104
secretin, 65, 104
severity of cystic fibrosis
genotype correlations, 61–3
socioeconomic status and, 64
variations, 23
shared care, 68–9, 71, 74
small intestinal biopsy, 13–14
social contacts, 54
social workers, 6, 16, 26, 33
socioeconomic status, 64
sodium
airway epithelial transport, 44–7
in sweat, 47, 65, 66
sodium channels, epithelial (ENaC), 47
soil
pathogenic bacteria, 53–5, 56
temperature, 56
South West Africa (now Namibia), 23
Spain, 62
Spastics Association, 39
St Mary’s Hospital, London, 42,
59–60, 64
staphylococcal chest infections, 5, 8
antibiotic therapy, 8–9
as cause of death, 49, 50
Staphylococcus aureus, 31, 64, 104
chest infections see staphylococcal 
chest infections
methicillin-resistant (MRSA), 53, 103
pathogenicity, 57, 58
penicillin sensitivity, 9, 58
steatorrhoea, 5, 104
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Stenotrophomonas maltophilia, 54, 55, 
104
stool
fat content, 65, 66
microscopy, 65
proteolytic enzymes, 5
streptomycin, 31
surgery, meconium ileus, 20
Survey, UK Cystic Fibrosis, 15, 19–20, 
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